

## ALLEGATO A

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di II fascia da ricoprire ai sensi dell'art. 18, comma 1, della Legge n. 240/2010 per il settore concorsuale \_\_06/E2 - Chirurgia Plastica-Ricostruttiva, Chirurgia Pediatrica e Urologia\_\_,

(settore scientifico-disciplinare \_\_\_\_\_MED/24 - Urologia\_\_\_\_\_)  
presso il Dipartimento di \_\_\_\_\_SCIENZE DELLA SALUTE\_\_\_\_\_, Codice concorso \_\_5373\_\_

## Matteo FERRO CURRICULUM VITAE

### INFORMAZIONI PERSONALI

COGNOME	FERRO
NOME	MATTEO
DATA DI NASCITA	17/01/1979

### TITOLI

#### TITOLO DI STUDIO

Laurea specialistica/magistrale in Medicina e Chirurgia - Università degli studi di Napoli Federico II  
- Valutazione 108/110  
Titolo della Tesi: Espressione dell'intero circuito dei geni HOX nel carcinoma vescicale umano  
Data di conseguimento: 07/10/2004

#### TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

- **Diploma di scuola di specializzazione in Urologia** - Università degli studi di Napoli Federico II - Valutazione 70/70 e lode  
Titolo della Tesi: Valutazione dell'espressione in vivo della proteina PTPD1 nei tumori della vescica.  
Data di conseguimento: 20/01/2010
- **Dottorato di Ricerca in: SCIENZE CHIRURGICHE E TECNOLOGIE DIAGNOSTICOTERAPEUTICHE AVANZATE** - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II - Indirizzo Urologico  
Tesi: Confronto tra Prostate Health Index (PHI) e Prostate Cancer Antigen3 (PCA3) in pazienti sottoposti a prima biopsia prostatica.  
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/24 - Urologia  
dal 01-01-2010 al 30-03-2013

#### ALTRI TITOLI CONSEGUITI

- **Abilitazione ASN- FASCIA: II** - Settore concorsuale 06/E2: CHIRURGIA PLASTICA-RICOSTRUTTIVA, CHIRURGIA PEDIATRICA E UROLOGIA  
Validità dal 20-05-2019 al 20-05-2030

- **Abilitazione ASN- FASCIA: I** - Settore concorsuale 06/E2: CHIRURGIA PLASTICA-RICOSTRUTTIVA, CHIRURGIA PEDIATRICA E UROLOGIA  
Validità dal Dal 01-06-2021 al 01-06-2032

## ATTIVITÀ DIDATTICA

### INSEGNAMENTI E MODULI

- **1) Docenza nell'ambito del Master Ricerca e Innovazione nelle Scienze della Salute (RISSI, Linea formative "Medicina Traslazionale")** - Modulo A 1.6-Medicina 2 Urologia - **4,5 ore di didattica frontale** - Pon 2007-2013-Università degli studi Salerno dal 15-10-2012 al 08-11-2012
- **2) Docenza a supplenza a titolo gratuito presso la scuola di specializzazione in Biochimica Clinica** sede SUN-Università degli studi di Napoli nel settore di insegnamento in Biochimica Clinica. Biomarcatori in Urooncologia. **10 Ore di didattica frontale** - dal 01-04-2015 al 01-06-2015
- **3) Insegnamento presso la Scuola di Specializzazione di Urologia dell'UNIMI: MODULO DI INSEGNAMENTO: Neurologia urologica ed urodinamica. 4 Ore di lezione frontale** - dal 01-01-2015 al 01-01-2016
- **4) Insegnamento presso la Scuola di Specializzazione di Urologia dell'UNIMI: MODULO DI INSEGNAMENTO: Patologia Apparato Uro-Genitale Maschile. 32 Ore di lezione frontale** - dal 01-01-2016 al 01-01-2017
- **5) Insegnamento presso 2° anno, 1° semestre Corso di Laurea in Infermieristica sez.IEO-UNIMI - Anno Accademico 2020/2021 - "Patologia del rene, della prostata e delle vie urinarie" - 21-12-2020 - 4 ore di didattica frontale**
- **6) Insegnamento nell'ambito del Master di II Livello in Chirurgia urologica robot-assistita - Anno accademico 2021/2022 Università degli Studi di Milano Via Festa del Perdono 7 - 20122 Milano: 6 ore di didattica frontale**
- **7) Insegnamento presso 2° anno, 1° semestre Corso di Laurea in Infermieristica sez.IEO-UNIMI - Anno Accademico 2021/2022 - "Patologie del rene: calcolosi urinaria e tumori renali" - 20-12-2021 - 4 ore di didattica frontale**
- **8) Insegnamento presso 2° anno, 1° semestre Corso di Laurea in Infermieristica sez.IEO-UNIMI - Anno Accademico 2022/2023 - "Patologia del rene, della prostata e delle vie urinarie" - 19-10-2022 - 4 ore di didattica frontale**

## ATTIVITÀ DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

### ATTIVITÀ DI RELATORE DI ELABORATI DI LAUREA, DI TESI DI LAUREA MAGISTRALE, DI TESI DI DOTTORATO E DI TESI DI SPECIALIZZAZIONE

- **Tesi di Specializzazione: UNIVERSITA' DEGLI STUDI DI MILANO - FACOLTA' DI MEDICINA E CHIRURGIA Scuola di Specializzazione in Urologia Anno Accademico 2016-2017 Dott. EMMANUEL DINANG CHEGUIE Correlatore: Chiar.mo Matteo Ferro**
- **Tesi del corso di laurea magistrale in Medicina e Chirurgia dell'Università degli Studi di Milano: AA 2018/2019 — Dott. D'Anna Gaetano (matr.841183) Ruolo prognostico preoperatorio del rapporto neutrofili/linfociti (NLR) nei pazienti sottoposti a nefroureterectomia per carcinoma uroteliale - Correlatore: Dr. Ferro Matteo**

• **Tesi del corso di laurea magistrale in Medicina e Chirurgia dell'Università degli Studi di Milano:** AA 2020-2021- Dott. Andrea Marmioli (matr. 872573), "L'impatto della pandemia da SARS-CoV-2 nella gestione del tumore vescicale non muscolo invasivo di alto grado: uno studio multicentrico" Correlatore: Dr. Ferro Matteo

#### **ATTIVITÀ DI TUTORATO DEGLI STUDENTI DI CORSI DI LAUREA E DI LAUREA MAGISTRALE E DI TUTORATO DI DOTTORANDI DI RICERCA**

- **1) Tutor per Tesi in Medicina e Chirurgia** - Matricola studente ID: 898955 A.A.2021/22
- **2) Tutor per Tesi in Medicina e Chirurgia** - Matricola studente ID: 872573 A.A.2021/22
- **3) Attività di tutorato presso The Doctoral School of Medicine and Pharmacy di Târgu Mureș** - Student: Baba Dragos Florin dal 01.10.2020 al 01.10.2021 - Strategies in early detection of neoplastic diseases in men.
- **4) Attività di tutorato presso The Doctoral School of Medicine and Pharmacy di Târgu Mureș** - Student: Chiujdea Sever dal 01.10.2020 ad oggi - Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.
- **5) Tutor A.A.2015/2016 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I/II semestre: studente Alessandro Serino (2° anno)
- **6) Tutor A.A.2016/2017 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I/II semestre: studenti - Matteo Turetti (2° anno) - Andrea Conti (4° anno)
- **7) Tutor A.A.2017/2018 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I semestre: studente Giulia Garelli (2° anno); II semestre: studente Lorusso Vito (2° anno)
- **8) Tutor A.A.2018/2019 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I/II semestre: studenti - Mattia Piccinelli (1° anno) - Francesco Botticelli (2° anno)
- **9) Tutor A.A.2020/2021 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I semestre: studenti - Marmioli Andrea (1° anno) - Nizzardo Marco (1° anno) - Piccinelli Mattia (3° anno); II semestre: studenti - Marmioli Andrea (1° anno) - Nizzardo Marco (1° anno)
- **10) Tutor A.A.2021/2022 Scuola di specializzazione in Urologia, Università degli studi di Milano:** I/II semestre: studenti - Graps Giorgio (1° anno) - Tozzi Marco (3° Anno)

#### **SEMINARI**

- **1) PhD lectures at The Doctoral School of Medicine and Pharmacy "Gheorghe Marinescu" of Târgu Mureș - Romania.** Title: "How to do a research project" - 4 hours - 23-08-2020
- **2) PhD lectures at The Doctoral School of Medicine and Pharmacy "Gheorghe Marinescu" of Târgu Mureș - Romania.** Title: "How to build a database and basic principles for clinical research" - 4 hours - 20-10-2020
- **3) Lectio del master di secondo livello in Alta Formazione e Qualificazione in Chirurgia Urologica Robot-Assistita - Anno Accademico 2021/2022 Università degli Studi di Milano - Titolo:** "Video-recorded step by step surgery: casi complessi e chirurgia di salvataggio"
- **4) Lectio del master di secondo livello in Alta Formazione e Qualificazione in Chirurgia Urologica Robot-Assistita - Anno Accademico 2021/2022 Università degli Studi di Milano - Titolo:** "Video-recorded step by step surgery: enucleoresezione renale robot-assistita, surgical skills e gestione casi complessi"
- **5) Lectio del master di secondo livello in Alta Formazione e Qualificazione in Chirurgia Urologica Robot-Assistita - Anno Accademico 2021/2022 Università degli Studi di Milano - Titolo:** "Video-recorded step by step surgery: nefroureterectomia robot-assistita."
- **6) PhD lectures at The Doctoral School of Medicine and Pharmacy "Gheorghe Marinescu" of Târgu Mureș - Romania.** Title: "Data interpretation and results discussions of the research projects" - 4 hours - 15-06-2022

## ATTIVITÀ DI RICERCA SCIENTIFICA

### PUBBLICAZIONI SCIENTIFICHE

Scopus ID: 22834576900    H-Index: 40    Total citations: 5131    Totale Impact factor: 1076.46

Totale Pubblicazioni: 299 indicizzate su Scopus + 1 non indicizzata

Primo Nome: 48    Ultimo Nome: 15    Corresponding author: 50

- **1) Ferro M** et al. Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. *Diagnostics (Basel)*. 2023 Jul 7;13(13):2308. doi: 10.3390/diagnostics13132308. PMID: 37443700.
- **2) Aveta A, Cilio S, Contieri R, Spena G, Napolitano L, Manfredi C, Franco A, Crocero F, Cerrato C, Ferro M** et al. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. *Int J Mol Sci*. 2023 Jun 29;24(13):10846. doi: 10.3390/ijms241310846. PMID: 37446024.
- **3) Crocetto F, Ferro M** et al. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. *Crit Rev Oncol Hematol*. 2023 Aug;188:104059. doi: 10.1016/j.critrevonc.2023.104059. Epub 2023 Jun 21. PMID: 37353178.
- **4) Ferro M** et al. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Clin Genitourin Cancer*. 2023 May 27:S1558-7673(23)00137-4. doi: 10.1016/j.clgc.2023.05.017. Epub ahead of print. PMID: 37419854.
- **5) Douglawi A, Ghoreifi A, Carbonara U, Yip W, Uzzo RG, Margulis V, Ferro M** et al. Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group. *Clin Genitourin Cancer*. 2023 May 24:S1558-7673(23)00130-1. doi: 10.1016/j.clgc.2023.05.011. PMID: 37301663.
- **6) Lasorsa F, Rutigliano M, Milella M, Ferro M** et al. Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma. *J Clin Med*. 2023 Jun 7;12(12):3888. PMID: 37373581.
- **7) Mazzola GC, Vincini MG, Rondi E, Ronci G, Vigorito S, Zaffaroni M, Corrao G, Gallo S, Zerini D, Durante S, Mistretta FA, Luzzago S, Ferro M** et al. CyberKnife Ultra-Hypofractionated SBRT for Localized Prostate Cancer with Dose Escalation to the Dominant Intraprostatic Lesion: In Silico Planning Study. *Applied Sciences*. 2023; 13(12):7273. Doi: 10.3390/app13127273.
- **8) Piccinelli ML, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M** et al. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. *European Urology Open Science*. 2023 Jul;53:109-115. doi: 10.1016/j.euros.2023.05.005
- **9) Barone B, Napolitano L, Calace FP, Del Biondo D, Napodano G, Grillo M, Reccia P, De Luca L, Prezioso D, Muto M, Crocetto F, Ferro M**. Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer. *Diagnostics (Basel)*. 2023 Jun 1;13(11):1939. doi: 10.3390/diagnostics13111939. PMID: 37296791.
- **10) Piccinelli ML, Panunzio A, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Tian Z, Luzzago S, Mistretta FA, Ferro M** et al. Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. *Minerva Urol Nephrol*. 2023 Jun;75(3):319-328. doi: 10.23736/S2724-6051.23.05151-0. PMID: 37221827.
- **11) Bada M, Crocetto F, Nyirady P, Pagliarulo V, Rapisarda S, Aliberti A, Boccasile S, Ferro M** et al. Inguinal lymphadenectomy in penile cancer patients: a comparison between open and video endoscopic approach in a multicenter setting. *J Basic Clin Physiol Pharmacol*. 2023 Mar 20;34(3):383-389. doi: 10.1515/jbcpp-2023-0038. PMID: 36933235.
- **12) Busetto GM, Finati M, Chirico M, Cinelli F, D'Altia N, Falagarino UG, Sanguedolce F, Del Giudice F, De Berardinis E, Ferro M** et al. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle? *World J Urol*. 2023 May;41(5):1329-1335. doi: 10.1007/s00345-023-04372-5. Epub 2023 Mar 27. PMID: 36971825.
- **13) Barone B, Mirto BF, Falcone A, Del Giudice F, Aveta A, Napolitano L, Del Biondo D, Ferro M** et al. The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial. *J Clin Med*. 2023 Apr 9;12(8):2784. doi: 10.3390/jcm12082784. PMID: 37109121.
- **14) Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M** et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. *Biomedicines*. 2023 Apr 2;11(4):1071. doi: 10.3390/biomedicines11041071. PMID: 37189689.
- **15) Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, Viscuso P, Salciccia S, Sciarra A, D'Andrea D, Pradere B, Moschini M, Mari A, Albisinni S, Krajewski W, Szydelko T, Matkiewicz B, Nowak L, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Soria F, Mori K, Tully KH, Pichler R, Ferro M** et al.

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. *Cancers (Basel)*. 2023 Mar 23;15(7):1937. doi: 10.3390/cancers15071937. PMID: 37046598.

•**16)** Piccinelli ML, Morra S, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Luzzago S, Mistretta FA, **Ferro M** et al. Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma. *Cancers (Basel)*. 2023 Apr 5;15(7):2155. doi: 10.3390/cancers15072155. PMID: 37046815.

•**17)** Contieri R, Hurler R, Paciotti M, Casale P, Saita A, Porpiglia F, Fiori C, Barone B, Crocetto F, Lucarelli G, Busetto GM, Del Giudice F, Maggi M, Cantiole F, Damiano R, Borghesi M, Bove P, Bertolo R, Papalia R, Mari A, Luzzago S, Mistretta FA, Soria F, Gontero P, Marchioni M, La Civita E, Terracciano D, Russo GI, Schips L, Perdoni S, Mirone V, Tataru OS, Musi G, Vartolomei MD, Autorino R, Montanari E, DE Cobelli O, **Ferro M**. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. *Minerva Urol Nephrol*. 2023 Apr;75(2):180-187. doi: 10.23736/S2724-6051.22.04953-9. Epub 2022 Oct 5. PMID: 36197700.

•**18)** Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E, Sciarra A, Russo G, Mancini V, D'Altia N, **Ferro M** et al. Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence. *J Pers Med*. 2023 Mar 13;13(3):512. doi: 10.3390/jpm13030512.

•**19)** **Ferro M** et al. Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects. *Int J Mol Sci*. 2023 Feb 27;24(5):4615. doi: 10.3390/ijms24054615. PMID: 36902045.

•**20)** Gentile F, La Civita E, Ventura BD, **Ferro M** et al. A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer. *Cancers (Basel)*. 2023 Feb 21;15(5):1355. doi: 10.3390/cancers15051355.

•**21)** Tataru OS, Marchioni M, Crocetto F, Barone B, Lucarelli G, Del Giudice F, Busetto GM, Vecchia A, Lo Giudice A, Russo GI, Luzzago S, Piccinelli ML, Vartolomei MD, Musi G, **Ferro M**. Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques. *Diagnostics (Basel)*. 2023 Feb 6;13(4):593. doi: 10.3390/diagnostics13040593. PMID: 36832081.

•**22)** Del Giudice F, Kim W, Li S, DE Berardinis E, Sciarra A, Salciccia S, **Ferro M** et al. Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and perioperative outcomes. *Minerva Urol Nephrol*. 2023 Feb;75(1):73-84. doi: 10.23736/S2724-6051.22.05073-X. Epub 2022 Oct 5. PMID: 36197701.

•**23)** Russo GI, Asmundo MG, Lo Giudice A, Trefiletti G, Cimino S, **Ferro M** et al. Is There a Role of Warburg Effect in Prostate Cancer Aggressiveness? Analysis of Expression of Enzymes of Lipidic Metabolism by Immunohistochemistry in Prostate Cancer Patients (DIAMOND Study). *Cancers (Basel)*. 2023 Feb 2;15(3):948. doi: 10.3390/cancers15030948. PMID: 36765905.

•**24)** Mistretta FA, Luzzago S, Alessi S, Piccinelli M, Marvaso G, Giudice AL, Nizzardo M, Cozzi G, Fontana M, Corrao G, **Ferro M** et al. Conditional survival of patients with low-risk prostate cancer: Temporal changes in active surveillance permanence over time. *Urol Oncol*. 2023 Jul;41(7):323.e1-323.e8. doi:10.1016/j.urolonc.2023.03.006.

•**25)** **Ferro M** et al. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. *Ther Adv Urol*. 2023 Apr 17;15:17562872231164803. doi: 10.1177/17562872231164803. PMID: 37113657.

•**26)** Alba S, Fimognari D, Crocero F, Ascalone L, Pullano C, Chiaravallotti F, Chiaradia F, Carbonara U, **Ferro M** et al. Neuraxial anesthesia versus general anesthesia in patients undergoing three-dimensional laparoscopic radical prostatectomy: Preliminary results of a prospective comparative study. *Asian Journal of Urology*. Epub 2022 Oct 04. doi: 10.1016/j.ajur.2022.04.006

•**27)** di Meo NA, Lasorsa F, Rutigliano M, Milella M, **Ferro M** et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. *Expert Rev Mol Diagn*. 2023 Apr;23(4):297-313. doi: 10.1080/14737159.2023.2195553. Epub 2023 Mar 28. PMID: 36960789.

•**28)** Piccinelli ML, Barletta F, Tappero S, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, **Ferro M** et al. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2023 Apr 4:S2405-4569(23)00082-2. doi: 10.1016/j.euf.2023.03.014. Epub ahead of print. PMID: 37024421.

•**29)** Lasorsa F, di Meo NA, Rutigliano M, **Ferro M** et al. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer. *Int J Mol Sci*. 2023 Jan 4;24(2):910. doi: 10.3390/ijms24020910. PMID: 36674430.

•**30)** Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo RG, Sundaram C, Rha KH, Gonzalgo ML, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, **Ferro M** et al. Corrigendum re "A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)" [*Eur Urol Focus* 2022;8:173-81]. *Eur Urol Focus*. 2022 Dec 30:S2405-4569(22)00294-2. doi: 10.1016/j.euf.2022.12.010. Erratum for: *Eur Urol Focus*. 2022 Jan;8(1):173-181. PMID: 36588010.

•**31)** Luzzago S, Mistretta FA, Mauri G, Vaccaro C, Ghilardi G, Maiettini D, Marmioli A, Varano G, Di Trapani E, Camisassi N, Bianchi R, Della Vigna P, **Ferro M** et al. Thermal ablation for small renal masses: Identifying the most appropriate tumor size cut-off for predicting perioperative and oncological outcomes. *Urol Oncol*. 2022 Dec;40(12):537.e1-537.e9. doi: 10.1016/j.urolonc.2022.08.008. Epub 2022 Oct 9. PMID: 36224057.

- 32)** Del Giudice F, Yoo KH, Lee S, Oh JK, Cho HJ, Kim SY, Min GE, Lee SH, Kim W, Li S, Wei W, Huang J, Brown DR, Spradling K, Basran S, Belladelli F, Autorino R, Pandolfo SD, Crivellaro S, Crocetto F, **Ferro M** et al. Characteristics of Sepsis or Acute Pyelonephritis Combined with Ureteral Stone in the United States: A Retrospective Analysis of Large National Cohort. *Applied Sciences* (Switzerland). 2022. vol. 12, no. 21, 10718. <https://doi.org/10.3390/app122110718>.
- 33)** di Meo NA, Lasorsa F, Rutigliano M, Loizzo D, **Ferro M** et al. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. *Int J Mol Sci*. 2022 Nov 18;23(22):14360. doi: 10.3390/ijms232214360. PMID: 36430837.
- 34)** Mistretta FA, de Cobelli O, Verze P, Botticelli F, Jannello L, Luzzago S, Cozzi G, Bianchi R, Di Trapani E, **Ferro M** et al. A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. *Asian J Androl*. 2022 Nov-Dec;24(6):579-583. doi: 10.4103/aja2021132. PMID: 35381697.
- 35)** Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Jannello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocerossa F, Cantiello F, D'Andrea D, Di Cosmo F, Porpiglia F, Ditunno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, Shariat SF, Di Nicola M, Minervini A, **Ferro M** et al. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). *World J Urol*. 2022 Nov;40(11):2771-2779. doi: 10.1007/s00345-022-04156-3. Epub 2022 Oct 6. PMID: 36203101.
- 36)** Cozzi G, Musi G, **Ferro M** et al. Progress in prostate cancer prevention. *Eur J Cancer Prev*. 2022 Nov 1;31(6):554-557. doi: 10.1097/CEJ.0000000000000745. Epub 2022 Mar 29. PMID: 35352690.
- 37)** Aveta A, Cacciapuoti C, Barone B, Di Zazzo E, Del Giudice F, Maggi M, **Ferro M** et al. The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? *Cancers* (Basel). 2022 Sep 29;14(19):4775. doi: 10.3390/cancers14194775. PMID: 36230700.
- 38)** Palumbo C, Bruni A, Antonelli A, Artibani W, Bassi P, Bertoni F, Borghetti P, Bracarda S, Cicchetti A, Corvò R, Gacci M, Ingrosso G, Magrini SM, Maruzzo M, Mirone V, Montironi R, Muto G, Noale M, Porreca A, Russi E, Triggiani L, Tubaro A, Valdagni R, Maggi S, Conti GN, Alitto AR, Ambrosi E, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Bigazzi B, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini Francolini D, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo R, da Pozzo L, D'Agostino D, D'Andrea D, Dandrea M, de Angelis M, de Cobelli O, de Concilio B, de Lisa A, de Luca S, de Stefani A, Deantoni CL, Degli Esposti C, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Fabiano M, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. *Minerva Urol Nephrol*. 2022 Feb;74(1):11-20. doi: 10.23736/S2724-6051.20.04032-1. Epub 2021 Jan 13. PMID: 33439570.
- 39)** Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti GN, Corvò R, DE Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, Crepaldi G, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Bigazzi B, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallinifancolini D, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, Cristiano O, D'Angelillo R, Da Pozzo L, D'Agostino D, D'Andrea D, Dandrea M, Deangelis M, Decobelli O, Deconcilio B, Delisa A, Deluca S, De Stefani A, Lucrezia Deantoni C, Degliesposti C, Destito A, Detti B, Dimuzio N, Distasio A, Distefano C, Ditrapani D, Difino G, Fabiano M, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. *Minerva Urol Nephrol*. 2022 Feb;74(1):38-48. doi: 10.23736/S2724-6051.20.03925-9. Epub 2020 Nov 17. PMID: 33200896.
- 40)** Del Giudice F, Oh JK, Basran S, Nicaise E, Song PH, Kim W, Kim SY, Min GE, Yoo KH, Cho HJ, Lee S, Sciarra A, Saliccia S, De Berardinis E, Asero V, Scornajenghi CM, Pradere B, Krajewski W, Gallioli A, **Ferro M** et al. Recent Trends in the Diagnostic and Surgical Management of Benign Prostatic Hyperplasia in the U.S. from 2004 to 2017: Annual Changes in the Selection of Treatment Options and Medical Costs. *Applied Sciences*. 2022; 12(17):8697. doi: 10.3390/app12178697.
- 41)** **Ferro M** et al. Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer. *Diagnostics* (Basel). 2022 Aug 16;12(8):1981. doi: 10.3390/diagnostics12081981. PMID: 36010331.
- 42)** Vartolomei MD, **Ferro M** et al. Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. *Current Opinion in Urology*. 2022 Sep 1;32(5):575-583. doi: 10.1097/MOU.0000000000001010. Epub 2022 Jun 24. PMID: 35749398.
- 43)** Hakimi K, Carbonara U, Djaladat H, Mehrazin R, Eun D, Reese A, Gonzalgo ML, Margulis V, Uzzo RG, Porter J, Sundaram CP, Abdollah F, Motttrie A, Tellini R, **Ferro M** et al. Outcomes of Lymph Node Dissection in

Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry. *Journal of Urology*. 2022 Aug;208(2):268-276. doi: 10.1097/JU.0000000000002690. PMID: 35377778.

•44) Soria F, Pradere B, Hurle R, D'Andrea D, Albisinni S, Diamand R, Laukhtina E, Di Trapani E, Aziz A, Krajewski W, Teoh JY, Mari A, Moschini M, Chiancone F, Autorino R, Porreca A, Marchioni M, Liguori G, Lucarelli G, Busetto GM, Foschi N, Antonelli A, Bove P, Russo GI, Crisan N, Borghesi M, Boeri L, Vecchia A, Greco F, Longo N, De Cobelli O, Shariat SF, Gontero P, **Ferro M** et al. Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery. *European Urology Open Science*. 2022 Jun 13;42:1-8. doi:10.1016/j.euros.2022.05.010.

•45) Vartolomei L, Cotruş A, Stanciu C, Delcea C, Tozzi M, Lievore E, Crocetto F, Del Giudice F, Lucarelli G, Muto M, **Ferro M**. Quality of Life and Psychological Distress among Patients with Small Renal Masses. *Journal of Clinical Medicine*. 2022 Jul 7;11(14):3944. doi: 10.3390/jcm11143944. PMID: 35887708.

•46) Romano L, Pellegrino R, Sciorio C, Barone B, Gravina AG, Santonastaso A, Mucherino C, Astretto S, Napolitano L, Aveta A, Pandolfo SD, Loizzo D, Del Giudice F, **Ferro M** et al. Erectile and sexual dysfunction in male and female patients with celiac disease: A cross-sectional observational study. *Andrology*. 2022 Jul;10(5):910-918. doi: 10.1111/andr.13186. Epub 2022 Apr 26. PMID: 35419983.

•47) Del Giudice F, Belladelli F, Chen T, Glover F, Mulloy EA, Kasman AM, Sciarra A, Salciccia S, Canale V, Maggi M, **Ferro M** et al. The association of impaired semen quality and pregnancy rates in assisted reproduction technology cycles: Systematic review and meta-analysis. *Andrologia*. 2022 Jul;54:e14409. doi:10.1111/and.14409.

•48) Monti M, Lunardini S, Magli IA, Campi R, Primiceri G, Berardinelli F, Amparore D, Terracciano D, Lucarelli G, Schips L, **Ferro M** et al. Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. *Biomedicines*. 2022 May 31;10(6):1287. doi: 10.3390/biomedicines10061287. PMID: 35740309.

•49) Vitale G, Caraglia M, Jung V, Kamradt J, Gentilini D, Di Martino MT, Dicitore A, Abate M, Tagliaferri P, Itró A, **Ferro M** et al. Molecular Characterization of Cancer Associated Fibroblasts in Prostate Cancer. *Cancers (Basel)*. 2022 Jun 14;14(12):2943. doi: 10.3390/cancers14122943. PMID: 35740605.

•50) Marchioni M, De Francesco P, Campi R, Carbonara U, **Ferro M** et al. Current management of radiation cystitis after pelvic radiotherapy: a systematic review. *Minerva Urology and Nephrology*. 2022 Jun;74(3):281-291. doi: 10.23736/S2724-6051.21.04539-0. Epub 2021 Oct 29. PMID: 34714035.

•51) Vecchia A, Carbonara U, Djaladat H, Mehazin R, Eun DD, Reese AC, Meng X, Uzzo R, Srivastava A, Porter J, Farrow JM, Jamil ML, Rosiello G, Tellini R, Mari A, Al-Qathani A, Rha KH, Wang L, Mastroianni R, **Ferro M** et al. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group). *Journal of Endourology*. 2022 Jun;36(6):752-759. doi: 10.1089/end.2021.0587. Epub 2022 Feb 25. PMID: 35019760.

•52) Piccinelli ML, Luzzago S, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Colombo A, **Ferro M** et al. Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. *World Journal of Urology*. 2022 Jun;40(6):1447-1454. doi: 10.1007/s00345-022-03983-8. Epub 2022 Mar 26. PMID: 35347414.

•53) Busetto GM, D'Agostino D, Colicchia M, Palmer K, Artibani W, Antonelli A, Bianchi L, Bocciardi A, Brunocilla E, Carini M, Carrieri G, Cormio L, Falagario UG, De Berardinis E, Sciarra A, Leonardo C, Del Giudice F, Maggi M, de Cobelli O, **Ferro M** et al. Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry. *Frontiers Oncology*. 2022 May 5;12:895460. doi: 10.3389/fonc.2022.895460. PMID: 35600337.

•54) Barone B, Calogero A, Scafuri L, **Ferro M** et al. Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. *Cancers (Basel)*. 2022 May 21;14(10):2545. doi: 10.3390/cancers14102545. PMID: 35626149.

•55) Mistretta FA, Luzzago S, Conti A, Verri E, Marvaso G, Collà Ruvolo C, Catellani M, Di Trapani E, Cozzi G, Bianchi R, **Ferro M** et al. Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. *Cancers (Basel)*. 2022 May 6;14(9):2313. doi: 10.3390/cancers14092313.

•56) Loizzo D, Pandolfo SD, Crocerossa F, Guruli G, **Ferro M** et al. Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice. *European Urology Open Science*. 2022 Mar 14;39:1-6. doi: 10.1016/j.euros.2022.02.009. PMID: 35309098.

•57) Fasanella D, Antonaci A, Esperto F, Scarpa RM, **Ferro M** et al. Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review. *Diagnosis (Berlin)*. 2021 Oct 22;9(2):157-165. doi: 10.1515/dx-2021-0080. PMID: 34674417.

•58) di Meo NA, Loizzo D, Pandolfo SD, Autorino R, **Ferro M** et al. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. *International Journal of Molecular Sciences*. 2022 Apr 10;23(8):4173. doi: 10.3390/ijms23084173. PMID: 35456991.

•59) Loizzo D, Pandolfo SD, Rogers D, Cerrato C, di Meo NA, Autorino R, Mirone V, **Ferro M** et al. Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. *International Journal of Molecular Sciences*. 2022 Mar 30;23(7):3826. doi: 10.3390/ijms23073826. PMID: 35409187.

•60) Del Giudice F, van Uem S, Li S, Vilson FL, Sciarra A, Salciccia S, Busetto GM, Maggi M, Tiberia L, Viscuso P, Canale V, Panebianco V, Pecoraro M, **Ferro M** et al. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or

Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. *Clinical Genitourinary Cancer*. 2022 Apr;20(2):198.e1-198.e9. doi: 10.1016/j.clgc.2021.11.016. PMID: 35031226.

•**61) Ferro M** et al. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. *Clin Genitourin Cancer*. 2022 Apr;20:e166-e172. doi:10.1016/j.clgc.2021.12.005.

•**62) Luzzago S, Piccinelli ML, Mistretta FA, Bianchi R, Cozzi G, Di Trapani E, Cioffi A, Catellani M, Fontana M, Jannello LMI, Botticelli FMG, Marvaso G, Alessi S, Pricolo P, Ferro M** et al. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. *BJU International*. 2022 Apr;129(4):524-533. doi: 10.1111/bju.15623. Epub 2021 Nov 10. PMID: 34687137.

•**63) Veccia A, Carbonara U, Derweesh I, Mehrazin R, Porter J, Abdollah F, Mazzone E, Sundaram CP, Gonzalgo M, Mastroianni R, Ghoreifi A, Cacciamani GE, Patel D, Marcus J, Danno A, Steward J, Satish Bhattu A, Asghar A, Reese AC, Wu Z, Uzzo RG, Minervini A, Rha KH, Ferro M** et al. Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. *Minerva Urology and Nephrology*. 2022 Apr;74(2):233-241. doi: 10.23736/S2724-6051.21.04247-8. Epub 2021 Mar 29. PMID: 33781022.

•**64) Ferro M** et al. Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. *Diagnostics (Basel)*. 2022 Feb 25;12(3):586. doi: 10.3390/diagnostics12030586. PMID: 35328139.

•**65) Lo Giudice A, Asmundo MG, Broggi G, Cimino S, Morgia G, Di Trapani E, Luzzago S, Musi G, Ferro M** et al. The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. *Applied Sciences*. 2022; 12(5):2268. doi: 10.3390/app12052268.

•**66) Del Giudice F, Flammia RS, Chung BI, Moschini M, Pradere B, Mari A, Soria F, Albisinni S, Krajewski W, Szydelko T, Laukhtina E, D'Andrea D, Gallioli A, Mertens LS, Maggi M, Sciarra A, Salciccia S, Ferro M** et al. Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. *Cancers (Basel)*. 2022 Feb 10;14:887. doi:10.3390/cancers14040887.

•**67) Crocetto F, Barone B, Ferro M** et al. Liquid biopsy in bladder cancer: State of the art and future perspectives. *Critical Reviews in Oncology/Hematology*. 2022 Feb;170:103577. doi: 10.1016/j.critrevonc.2022.103577. Epub 2022 Jan 5. PMID: 34999017.

•**68) Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Aydh A, Ferro M** et al. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. *World Journal of Urology*. 2022 Feb;40(2):443-451. doi: 10.1007/s00345-021-03864-6. PMID: 34687344.

•**69) Marchioni M, Marandino L, Amparore D, Berardinelli F, Mascitti M, Ferro M** et al. Factors influencing survival in metastatic castration-resistant prostate cancer therapy. *Expert Rev Anticancer Ther*. 2022 Oct;22(10):1061-1079. doi: 10.1080/14737140.2022.2114458. Epub 2022 Aug 30. PMID: 35982645.

•**70) Russo GI, Musso N, Lo Giudice A, Asmundo MG, Di Mauro M, Bonacci PG, Massimino M, Bivona D, Stefani S, Pricoco E, Ferro M** et al. PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer. *Journal of Cancer Research and Clinical Oncology*. 2022 Aug 16. doi: 10.1007/s00432-022-04262-0. Epub ahead of print. PMID: 35972693.

•**71) Terracciano D, La Civita E, Athanasiou A, Liotti A, Fiorenza M, Cennamo M, Crocetto F, Tennstedt P, Schiess R, Haese A, Ferro M** et al. New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index. *Prostate*. 2022 Nov;82(15):1469-1476. doi: 10.1002/pros.24422. PMID: 35971798.

•**72) Kenigsberg AP, Carpinito G, Gold SA, Meng X, Ghoreifi A, Djaladat H, Minervini A, Jamil M, Abdollah F, Farrow JM, Sundaram C, Uzzo R, Ferro M, Meagher M, Derweesh I, Wu Z, Porter J, Katims A, Mehrazin R, Motttrie A, Simone G, Reese AC, Eun DD, Bhattu AS, Gonzalgo ML, Carbonara U, Autorino R, Margulis V.** Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomy. *Urol Oncol*. 2022 Oct;40(10):452.e17-452.e23. doi: 10.1016/j.urolonc.2022.06.006. Epub 2022 Aug 4. PMID: 35934609.

•**73) Ferro M** et al. Radiomics in prostate cancer: an up-to-date review. *Therapeutic Advances in Urology*. 2022 Jul 4;14:17562872221109020. doi: 10.1177/17562872221109020. PMID: 35814914.

•**74) Stangl-Kremser J, Lambertini L, Di Maida F, Martinez-Fundichely A, Ferro M** et al. Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. *Eur Urol Focus*. 2022 Nov;8(6):1622-1626. doi: 10.1016/j.euf.2022.06.004. Epub 2022 Jun 27. PMID: 35773181.

•**75) Del Giudice F, Huang J, Li S, Sorensen S, Enemchukwu E, Maggi M, Salciccia S, Ferro M** et al. Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States. *Prostate Cancer Prostatic Dis*. 2023 Jun;26(2):367-373. doi: 10.1038/s41391-022-00558-x. Epub 2022 Jun 21. PMID: 35729329.

•**76) Ferro M** et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. *Urol Oncol*. 2022 Nov;40(11):490.e13-490.e20. doi: 10.1016/j.urolonc.2022.05.016. Epub 2022 Jun 5. PMID: 35676172.

•**77) Gentile F, La Civita E, Della Ventura B, Ferro M** et al. A Combinatorial Neural Network Analysis Reveals a Synergistic Behaviour of Multiparametric Magnetic Resonance and Prostate Health Index in the Identification of Clinically Significant Prostate Cancer. *Clin Genitourin Cancer*. 2022 Oct;20(5):e406-e410. doi: 10.1016/j.clgc.2022.04.013. Epub 2022 Apr 29. PMID: 35610113.

- 78)** Vartolomei L, Cotruș A, Tătaru SO, Vartolomei MD, Man A, **Ferro M** et al. Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. *Aging Male*. 2022 Dec;25(1):62-66. doi: 10.1080/13685538.2022.2040981. PMID: 35179090.
- 79)** **Ferro M** et al. Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. *Urologia Internationalis*. 2022;106(1):75-82. doi: 10.1159/000516680. Epub 2021 Jun 24. PMID: 34167120.
- 80)** Broggi G, Lo Giudice A, Di Mauro M, Pricoco E, Piombino E, **Ferro M** et al. Insulin signaling, androgen receptor and PSMA immunohistochemical analysis by semi-automated tissue microarray in prostate cancer with diabetes (DIAMOND study). *Translational Research*. 2021 Dec;238:25-35. doi: 10.1016/j.trsl.2021.07.002. Epub 2021 Jul 24. PMID: 34314871.
- 81)** Bertolo R, Vittori M, Cipriani C, Maiorino F, Iacovelli V, Petta F, Toschi N, **Ferro M** et al. Is thulium laser vapoenucleation of the prostate equally safe and effective in elderly patients? A propensity score matched analysis of early perioperative and functional outcomes. *Actas Urologicas Espanolas (Engl Ed)*. 2021 Dec;45(10):648-655. English, Spanish. doi: 10.1016/j.acuroe.2020.09.011. Epub 2021 Nov 11. PMID: 34776396.
- 82)** Da Col T, Caccianiga G, Catellani M, Mariani A, **Ferro M** et al. Automating Endoscope Motion in Robotic Surgery: A Usability Study on da Vinci-Assisted Ex Vivo Neobladder Reconstruction. *Frontiers in Robotics and AI*. 2021 Nov 25;8:707704. doi: 10.3389/frobt.2021.707704. PMID: 34901168.
- 83)** La Civita E, Liotti A, Cennamo M, Crocetto F, **Ferro M** et al. Peri-Prostatic Adipocyte-Released TGFβ Enhances Prostate Cancer Cell Motility by Upregulation of Connective Tissue Growth Factor. *Biomedicines*. 2021 Nov 15;9(11):1692. doi: 10.3390/biomedicines9111692. PMID: 34829922.
- 84)** Crocetto F, di Zazzo E, Buonerba C, Aveta A, Pandolfo SD, Barone B, Trama F, Caputo VF, Scafuri L, **Ferro M** et al. Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. *Nutrients*. 2021 Oct 23;13(11):3750. doi: 10.3390/nu13113750. PMID: 34836005.
- 85)** **Ferro M** et al. The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. *Cancers (Basel)*. 2021 Oct 21;13(21):5276. doi: 10.3390/cancers13215276. PMID: 34771440.
- 86)** Tătaru OS, Martha O, Crocetto F, Barone B, Voidazan S, Borda A, Sin A, Hutanu A, Loghin A, Sin I, Porav-Hodade D, Chibelea CB, Vartolomei L, Lucarelli G, **Ferro M** et al. Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study. *Future Science OA*. 2021 Jun 30;7(9):FSO745. doi: 10.2144/fsoa-2021-0051. PMID: 34737886.
- 87)** Scafuri L, Sciarra A, Crocetto F, **Ferro M** et al. Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma? *Future Science OA*. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092. PMID: 34737893.
- 88)** **Ferro M** et al. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. *Future Oncology*. 2021 Oct;17(30):3987-3994. doi: 10.2217/fon-2020-1298. Epub 2021 Jul 19. PMID: 34278815.
- 89)** Luzzago S, Serino A, Aurilio G, Mistretta FA, Piccinelli ML, Lorusso V, Morelli M, Bianchi R, Catellani M, Cozzi G, Di Trapani E, Cioffi A, Verri E, **Ferro M** et al. Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. *Urologic Oncology*. 2021 Oct;39(10):736.e1-736.e7. doi: 10.1016/j.urolonc.2021.06.020. Epub 2021 Jul 21. PMID: 34301457.
- 90)** Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L, Verde A, Bruzzese D, Iaccarino S, Costabile F, Onofrio L, Viggiani M, Palmieri A, De Placido P, Marretta AL, Pietroluongo E, Luce A, Abate M, Navaeisiddighi Z, Caputo VF, Celentano G, Longo N, **Ferro M** et al. Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. *Clinical Genitourinary Cancer*. 2021 Oct;19:e286-e298. doi: 10.1016/j.clgc.2021.03.021. Epub 2021 Apr 3. PMID: 33958297.
- 91)** Sciarra A, Viscuso P, Arditi A, Mariotti G, De Berardinis E, Di Pierro GB, Canale V, Gentilucci A, Maria Busetto G, Maggi M, Eisenberg ML, Vilson F, Chung BI, **Ferro M** et al. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. *International Journal of Clinical Practice*. 2021 Oct;75(10):e14208. doi: 10.1111/ijcp.14208. Epub 2021 May 4. PMID: 33811418.
- 92)** Carbonara U, Srinath M, Crocerossa F, **Ferro M** et al. Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: an evidence-based analysis of comparative outcomes. *World Journal of Urology*. 2021 Oct;39(10):3721-3732. doi: 10.1007/s00345-021-03687-5. Epub 2021 Apr 11. PMID: 33843016.
- 93)** Del Giudice F, Busetto GM, Gross MS, Maggi M, Sciarra A, Salciccia S, **Ferro M** et al. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. *Journal of Cancer Research and Clinical Oncology*. 2021 Oct;147(10):3073-3080. doi: 10.1007/s00432-021-03571-0. PMID: 33675400.
- 94)** **Ferro M** et al. Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression? *Frontiers in Oncology*. 2021 Sep 9;11:754649. doi: 10.3389/fonc.2021.754649. PMID: 34568079.

- 95)** Ferro M et al. Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer. *Cancers (Basel)*. 2021 Sep 21;13(18):4723. doi: 10.3390/cancers13184723.
- 96)** Ferro M et al. Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization. *International Journal of Molecular Sciences*. 2021 Sep 15;22(18):9971. doi: 10.3390/ijms22189971. PMID: 34576134.
- 97)** Cantiello F, Fimognari D, Di Mauro M, Crocerossa F, Carbonara U, **Ferro M** et al. Mechanical and Ablative Minimally Invasive Techniques for Male LUTS due to Benign Prostatic Obstruction: A Systematic Review according to BPH-6 Evaluation. *Urologia Internationalis*. 2021;105(9-10):858-868. doi: 10.1159/000514438.PMID: 33849045.
- 98)** Luzzago S, Mistretta FA, Dossena E, Comandi G, Petralia G, Di Trapani D, Cozzi G, Galfano A, **Ferro M** et al. Uro-oncologic patient management during the COVID-19 pandemic: survey findings from an Italian oncologic hub. *Future Oncology*. 2021 Sep;17(27):3615-3625. doi: 10.2217/fon-2021-0145. Epub 2021 Jul 19. PMID: 34278823.
- 99)** Katims AB, Say R, Derweesh I, Uzzo R, Minervini A, Wu Z, Abdollah F, Sundaram C, **Ferro M** et al. Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). *The Journal of Urology*. 2021 Sep;206(3):568-576. doi: 10.1097/JU.0000000000001786. Epub 2021 Apr 21. Erratum in: *J Urol*. 2022 Apr;207(4):943. PMID: 33881931.
- 100)** Marvaso G, Corrao G, Zaffaroni M, Pepa M, Augugliaro M, Volpe S, Musi G, Luzzago S, Mistretta FA, Verri E, Cossu Rocca M, **Ferro M** et al. Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. *Frontiers in Oncology*. 2021 Aug 4;11:732766. doi: 10.3389/fonc.2021.732766. PMID: 34422672.
- 101)** Bianchi R, Mistretta FA, Musi G, Luzzago S, Morelli M, Lorusso V, Catellani M, Di Trapani E, Cozzi G, **Ferro M** et al. Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the "Shell" Technique. *Journal of Clinical Medicine*. 2021 Aug 16;10(16):3601. doi: 10.3390/jcm10163601. PMID: 34441897.
- 102)** **Ferro M** et al. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. *Future Science OA*. 2021 Apr 20;7(7):FSO709. doi: 10.2144/fsoa-2021-0008. PMID: 34258022.
- 103)** Del Giudice F, Kasman AM, Chen T, De Berardinis E, Busetto GM, Sciarra A, **Ferro M** et al. The Association between Mortality and Male Infertility: Systematic Review and Meta-analysis. *Urology*. 2021 Aug;154:148-157. doi: 10.1016/j.urology.2021.02.041. Epub 2021 Apr 2. PMID: 33819517.
- 104)** **Ferro M** et al. The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. *Minerva Urology and Nephrology*. 2021 Aug;73(4):442-451. doi: 10.23736/S2724-6051.21.04098-4. PMID: 33769016.
- 105)** Gentile F, **Ferro M** et al. Reply to Jue et al. Value of MRI to Improve Deep Learning Model That Identifies High-Grade Prostate Cancer. Comment on "Gentile et al. Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model. *Diagnostics* 2021, 11, 335". *Diagnostics (Basel)*. 2021 Jul 6;11(7):1214. doi: 10.3390/diagnostics11071214. PMID: 34359297.
- 106)** Franzese E, Falco S, Laterza MM, Montella L, Facchini S, Liguori C, Coppola P, Diessa Y, Berretta M, Pisconti S, Trama F, **Ferro M** et al. The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities. *Future Science OA*. 2021 Apr 7;7(6):FSO705. doi: 10.2144/fsoa-2021-0035. PMID: 34046207.
- 107)** Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, **Ferro M** et al. Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. *Frontiers in Endocrinology*. 2021 Jun 14;12:695170. doi: 10.3389/fendo.2021.695170.
- 108)** Maggi M, Salciccia S, Del Giudice F, Busetto GM, Falagario UG, Carrieri G, **Ferro M** et al. A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data. *Frontiers in Oncology*. 2021 Jun 8;11:700258. doi: 10.3389/fonc.2021.700258. PMID: 34169003.
- 109)** Marchioni M, Rivas JG, Autran A, Socarras M, Albisinni S, **Ferro M** et al. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. *Current Urology Reports*. 2021 Apr 22;22(6):31. doi: 10.1007/s11934-021-01050-0.
- 110)** Bruno SM, Falagario UG, d'Altilla N, Recchia M, Mancini V, Selvaggio O, Sanguedolce F, Del Giudice F, Maggi M, **Ferro M** et al. PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. *Frontiers in Oncology*. 2021 May 20;11:693684. doi: 10.3389/fonc.2021.693684. PMID: 34094990.
- 111)** **Ferro M** et al. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. *Frontiers in Oncology*. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. PMID: 34046347.
- 112)** Maggi M, Del Giudice F, Falagario UG, Cocci A, Russo GI, Di Mauro M, Sepe GS, Galasso F, Leonardi R, Iacona G, Carroll PR, Cooperberg MR, Porreca A, **Ferro M** et al. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. *Cancers (Basel)*. 2021 Apr 23;13(9):2047. doi: 10.3390/cancers13092047. PMID: 33922626.
- 113)** Liotti A, La Civita E, Cennamo M, Crocetto F, **Ferro M** et al. Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform. *Prostate*. 2021 May;81(7):407-417. doi: 10.1002/pros.24117. Epub 2021 Mar 18. PMID: 33734457.
- 114)** Salciccia S, Eisenberg ML, Maggi M, Lai S, Mastroianni CM, Pasculli P, Ciardi MR, Canale V, **Ferro M** et al. Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized

Male COVID-19 Patients. *Diagnostics (Basel)*. 2021 Mar 24;11(4):581. doi: 10.3390/diagnostics11040581. PMID: 33804969.

•**115)** Noale M, Bruni A, Triggiani L, Buglione M, Bertoni F, Frassinelli L, Montironi R, Corvò R, Zagonel V, Porreca A, Bassi P, Gacci M, Conti GN, Maggi S, Magrini S, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Bigazzi B, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruno G, Brunocilla E, Buffoli A, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzi E, Catalano G, Cattarino S, Catucci F, Francolini DC, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, Nunzio CD, Cristiano O, D'angelillo R, Da Pozzo L, D'agostino D, D'andrea D, Dandrea M, De Angelis M, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Esposti CD, Destito A, Detti B, Muzio ND, Stasio AD, Stefano CD, Trapani DD, Difino G, Fabiano M, Facondo G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study. *Cancers (Basel)*. 2021 Mar 23;13(6):1479. doi: 10.3390/cancers13061479. PMID: 33806994.

•**116)** Napodano G, **Ferro M** et al. High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology. *Diagnostics (Basel)*. 2021 Feb 26;11(3):400. doi: 10.3390/diagnostics11030400. PMID: 33652852.

•**117)** Tătaru OS, Vartolomei MD, Rassweiler JJ, Virgil O, Lucarelli G, Porpiglia F, Amparore D, Manfredi M, Carrieri G, Falagario U, Terracciano D, de Cobelli O, Busetto GM, Del Giudice F, **Ferro M**. Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives. *Diagnostics (Basel)*. 2021 Feb 20;11(2):354. doi: 10.3390/diagnostics11020354. PMID: 33672608.

•**118)** Gentile F, **Ferro M** et al. Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model. *Diagnostics (Basel)*. 2021 Feb 18;11(2):335. doi: 10.3390/diagnostics11020335. PMID: 33670632.

•**119)** **Ferro M** et al. Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. *Diagnostics (Basel)*. 2021 Feb 20;11(2):355. doi: 10.3390/diagnostics11020355. PMID: 33672650.

•**120)** Saliccia S, Rosati D, Viscuso P, Canale V, Scarrone E, Frisenda M, Catuzzi R, Moriconi M, Asero V, Signore S, De Dominicis M, Emiliozzi P, Carbone A, Pastore AL, Fuschi A, Di Pierro GB, Gentilucci A, Cattarino S, Mariotti G, Busetto GM, **Ferro M** et al. Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis. *Central European Journal of Urology*. 2021;74(4):503-515. doi: 10.5173/ceju.2021.0177. Epub 2021 Nov 29. PMID: 35083069.

•**121)** Porreca A, Schiavina R, Romagnoli D, Corsi P, Salvaggio A, D'Agostino D, **Ferro M** et al. T-L technique for HoLEP: perioperative outcomes of a large single-centre series. *Central European Journal of Urology*. 2021;74(3):366-371. doi: 10.5173/ceju.2021.3.105. Epub 2021 Jul 14. PMID: 34729227.

•**122)** Crocetto F, Buonerba C, Caputo V, **Ferro M** et al. Urologic malignancies: advances in the analysis and interpretation of clinical findings. *Future Science OA*. 2021 Feb 4;7(4):FSO674. doi: 10.2144/fsoa-2020-0210. PMID: 33815820.

•**123)** Porreca A, Colicchia M, Tafuri A, D'Agostino D, Busetto GM, Crestani A, Odorizzi K, Amigoni N, Rizzetto R, Gozzo A, Gallina S, Bianchi L, **Ferro M** et al. Perioperative Outcomes of Holmium Laser Enucleation of the Prostate: A Systematic Review. *Urol Int*. 2022;106(10):979-991. doi: 10.1159/000518560. PMID: 34569529.

•**124)** Crocetto F, Cimmino A, **Ferro M** et al. Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicine. *Journal of Basic and Clinical Physiology and Pharmacology*. 2021 Sep 27. doi: 10.1515/jbcpp-2021-0233. PMID: 34563104.

•**125)** Annese P, d'Altília N, Mancini V, Falagario UG, Del Giudice F, **Ferro M** et al. Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center. *Therapeutic Advances in Urology*. 2021 Jul 31;13:17562872211037109. doi: 10.1177/17562872211037109. PMID: 34377154.

•**126)** **Ferro M** et al. Narrative review of Mediterranean diet in Cilento: longevity and potential prevention for prostate cancer. *Therapeutic Advances in Urology*. 2021 Jul 22;13:17562872211026404. doi: 10.1177/17562872211026404. PMID: 35173812.

•**127)** D'Agostino D, Colicchia M, Corsi P, Romagnoli D, Del Rosso A, Modonutti D, Busetto GM, **Ferro M**. The combination of waterjet ablation (Aquabeam®) and holmium laser power for treatment of symptomatic benign prostatic hyperplasia: early functional results. *Central European Journal of Urology*. 2021;74(2):222-228. doi: 10.5173/ceju.2021.0049. Epub 2021 May 20. PMID: 34336242.

•**128)** Izzo A, Quarto G, Grimaldi G, Castaldo L, Muscariello R, Franzese D, Del Prete P, **Ferro M** et al. Robotic radical cystectomy with concomitant implantation of 3-piece penile prosthesis: a one-step solution. *Therapeutic Advances in Urology*. 2021 Jun 15;13:17562872211024512. doi: 10.1177/17562872211024512. PMID: 34188695.

•**129)** Cozzi G, Musi G, Milani M, Jemos C, Gandini S, Mazzoleni L, **Ferro M** et al. Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. *Integrative Cancer Therapies*. 2021 Jan-Dec; 20:15347354211019483. doi: 10.1177/15347354211019483. PMID: 34027701.

•**130)** Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, **Ferro M**. BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. *Diagnostics (Basel)*. 2021 May 19;11(5):908. doi: 10.3390/diagnostics11050908.

- 131)** Serretiello E, Folliero V, Santella B, Giordano G, Santoro E, De Caro F, Pagliano P, **Ferro M** et al. Trend of Bacterial Uropathogens and Their Susceptibility Pattern: Study of Single Academic High-Volume Center in Italy (2015-2019). *International Journal of Microbiology*. 2021 Apr 21;2021:5541706. doi: 10.1155/2021/5541706.
- 132)** **Ferro M** et al. Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. *Journal of Personalized Medicine*. 2021 Mar 23;11(3):237. doi: 10.3390/jpm11030237.
- 133)** Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, Bracarda S, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S, Alitto AR, Ambrosi E, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallinifrancolini D, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, Cristiano O, D'Agostino D, D'Andrea D, D'Angelillo R, Dapozzo L, Dandrea M, Deangelis M, Decobelli O, Deconcilio B, Delisa A, Deluca S, Denunzio C, Destefani A, Deantoni CL, Degliesposti C, Destito A, Detti B, Dimuzio N, Distasio A, Distefano C, Ditrapani D, Difino G, Fabiano M, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study). *Minerva Urologica e Nefrologica*. 2020 Oct;72(5):595-604. doi: 10.23736/S0393-2249.19.03637-3. Epub 2020 Jan 7. PMID: 31920063.
- 134)** Loizzo D, di Meo NA, Peluso MR, Rutigliano M, Matera M, Miacola C, Palella G, Tedeschi M, Spilotros M, **Ferro M** et al. Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation. *Transplantation*. 2021; 2(2):191-207. <https://doi.org/10.3390/transplantation2020018>
- 135)** Terreri S, Mancinelli S, **Ferro M** et al. Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. *Cancers (Basel)*. 2021 Feb 8;13(4):681. doi: 10.3390/cancers13040681. PMID: 33567603.
- 136)** Porreca A, D'Agostino D, Romagnoli D, Del Giudice F, Maggi M, Palmer K, Falabella R, De Berardinis E, Sciarra A, **Ferro M** et al. The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review of Randomized Control Trials. *Urologia Internationalis*. 2021;105(7-8):531-540. doi: 10.1159/000512582. Epub 2021 Feb 3. PMID: 33535221.
- 137)** **Ferro M** et al. Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. *Translational Andrology and Urology*. 2021 Feb;10(2):626-635. doi: 10.21037/tau-20-1272. PMID: 33718065.
- 138)** Zhenjie Wu, Qi Chen, Hooman Djaladat, Andrea Minervini, Robert G. Uzzo, Chandru Sundaramf, Koon H. Rha, Mark L. Gonzalgo, Reza Mehrzini, Elio Mazzone, Jamil Marcus, Alyssa Danno, James Porter, Aeen Asgharm, Fady Ghali, Georgi Guruli, Antoin Douglawi, Giovanni Cacciamani, Alireza Ghoreifi, Giuseppe Simone, Vitaly Margulis, **Matteo Ferro** et al. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). *European Urology Focus*. 2022 Jan;8(1):173-181. doi: 10.1016/j.euf.2021.01.014. Epub 2021 Feb 3. PMID: 33549537.
- 139)** Sciarra A, Maggi M, Del Proposto A, Magliocca F, Ciardi A, Panebianco V, De Berardinis E, Salicci S, Di Pierro G, Gentilucci A, Kasman A, Chung B, **Ferro M** et al. Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy. *Translational Andrology and Urology*. 2021 Jan; 10:66-76. doi:10.21037/tau-20-850.
- 140)** Cata E, Andras I, **Ferro M** et al. Systematic sampling during MRI-US fusion prostate biopsy can overcome errors of targeting-prospective single center experience after 300 cases in first biopsy setting. *Translational Andrology and Urology*. 2020 Dec;9(6):2510-2518. doi: 10.21037/tau-20-1001. PMID: 33457225.
- 141)** Di Trapani E, Luzzago S, Peveri G, Catellani M, **Ferro M** et al. A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. *Urologic Oncology*. 2021 Jan 7;S1078-1439(20)30626-8. doi:10.1016/j.urolonc.2020.11.040. PMID: 33423938.
- 142)** **Ferro M** et al. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. *Minerva Urologica e Nefrologica*. 2021 Jan 13. doi: 10.23736/S0393-2249.20.04076-X. PMID: 33439571.
- 143)** Busetto GM, Del Giudice F, Mari A, Sperduti I, Longo N, Antonelli A, Cerruto MA, Costantini E, Carini M, Minervini A, Rocco B, Artibani W, Porreca A, Porpiglia F, Damiano R, De Sio M, Arcaniolo D, Cimino S, Russo GI, Lucarelli G, Di Tonno P, Gontero P, Soria F, Trombetta C, Liguori G, Scarpa RM, Papalia R, Terrone C, Borghesi M, Verze P, Madonia M, De Lisa A, Bove P, Guazzoni G, Lughezzani G, Racioppi M, Di Gianfrancesco L, Brunocilla E, Schiavina R, Simeone C, Veccia A, Montorsi F, Briganti A, Dal Moro F, Pavone C, Serretta V, Di Stasi SM, Galosi AB, Schips L, Marchioni M, Montanari E, Carrieri G, Cormio L, Greco F, Musi G, Maggi M, Conti SL, Tubaro A, De Berardinis E, Sciarra A, Gallucci M, Mirone V, de Cobelli O, **Ferro M**. How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? *Frontiers in Surgery*. 2020 Nov 24;7:563006. doi:10.3389/fsurg.2020.563006. PMID: 33330604.
- 144)** Lucarelli G, **Ferro M** et al. Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. *Metabolites*. 2020 Dec 13;10(12):509. doi:10.3390/metabo10120509. PMID: 33322148.
- 145)** **Ferro M** et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. *Critical Reviews in Oncology/Hematology*. 2021 Jan;157:103198. doi: 10.1016/j.critrevonc. 2020.103198. Epub 2020 Dec 13. PMID: 33316417.

- 146)** Tellini R, Mari A, Muto G, Cacciamani GE, **Ferro M** et al. Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. *European Urology Oncology*. 2020 Nov 4;52588-9311(20)30171-1. doi: 10.1016/j.euo.2020.10.006. PMID: 33160975.
- 147)** Saliccia S, Del Giudice F, Maggi M, Eisenberg M, Chung BI, Conti SL, Kasman A, Vilson FL, **Ferro M** et al. Safety and Feasibility of Outpatient Surgery in Benign Prostatic Hyperplasia: a Systematic Review and Meta-analysis. *Journal of Endourology*. 2020 Oct 21. doi: 10.1089/end.2020.0538. PMID: 33081521.
- 148)** Del Giudice F, Kasman AM, Li S, Belladelli F, **Ferro M** et al. Increased Mortality Among Men Diagnosed With Impaired Fertility: Analysis of US Claims Data. *Urology*. 2021 Jan;147:143-149. doi: 10.1016/j.urology.2020.07.087.
- 149)** Luzzago S, de Cobelli O, Mistretta FA, Piccinelli ML, Lorusso V, Morelli M, Bianchi R, Catellani M, Cozzi G, Di Trapani E, Pricolo P, Alessi S, **Ferro M** et al. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. *Prostate Cancer and Prostatic Diseases*. 2020 Sep 28. doi: 10.1038/s41391-020-00290-4. PMID: 32989259.
- 150)** Mistretta FA, Musi G, Collà Ruvolo C, Conti A, Luzzago S, Catellani M, Di Trapani E, Cozzi G, Bianchi R, **Ferro M** et al. Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder. *Journal of Endourology*. 2020 Oct 30. doi: 10.1089/end.2020.0622. PMID: 32977727.
- 151)** Crocero F, Marchioni M, Novara G, Carbonara U, **Ferro M** et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. *Journal of Urology*. 2021 Feb; 205(2):356-369. doi: 10.1097/JU.0000000000001369. Epub 2020 Sep 16. PMID: 32935652.
- 152)** Porreca A, Del Giudice F, Giampaoli M, D'Agostino D, Romagnoli D, Corsi P, Del Rosso A, Maggi M, Chung BI, **Ferro M** et al. Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study. *Medicine (Baltimore)*. 2020 Sep 11;99(37):e22059. doi: 10.1097/MD.00000000000022059.
- 153)** Porreca A, Colicchia M, Busetto GM, **Ferro M**. MRI and Active Surveillance for Prostate Cancer. *Diagnostics (Basel)*. 2020 Aug 14;10(8):590. doi: 10.3390/diagnostics10080590. PMID: 32823810.
- 154)** Bertolo R, Cipriani C, **Ferro M** et al. Editorial Comment from Dr Bertolo et al. to Partial nephrectomy preserves renal function without increasing the risk of complications compared with radical nephrectomy for renal cell carcinomas of stages pT2-3a. *International Journal of Urology*. 2020 Oct;27:914. doi: 10.1111/iju.14334.
- 155)** Di Trapani E, Musi G, **Ferro M** et al. Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. *Scandinavian Journal of Urology*. 2020 Aug 10:1-5. doi:10.1080/21681805.2020.1798503. PMID: 32772805.
- 156)** Schiavina R, Mari A, Bianchi L, Amparore D, Antonelli A, Artibani W, Brunocilla E, Capitanio U, Fiori C, Di Maida F, Gontero P, Larcher A, Li Marzi V, Longo N, Marra G, Montanari E, Porpiglia F, Roscigno M, Simeone C, Siracusano S, Tellini R, Terrone C, Villari D, Ficarra V, Carini M, Minervini A, Altieri V, Berardinelli F, Borghesi M, Bravi CA, Bove P, Cacciamani GE, Campi R, Celia A, Costantini E, Da Pozzo L, Falsaperla M, **Ferro M** et al. Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORD 2 project). *European Journal of Surgical Oncology*. 2020 Jul;46:1353-1359. doi:10.1016/j.ejso.2020.01.022. Epub 2020 Jan 22. PMID: 32007380.
- 157)** **Ferro M** et al. Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. *World Journal of Urology*. 2020 Jul 18. doi: 10.1007/s00345-020-03368-9.
- 158)** Del Giudice F, Kasman AM, **Ferro M** et al. Clinical correlation among male infertility and overall male health: A systematic review of the literature. *Investigative and Clinical Urology*. 2020 Jul;61(4):355-371. doi: 10.4111/icu.2020.61.4.355. Epub 2020 Jun 8. PMID: 32665992.
- 159)** Porreca A, Bianchi FM, Salvaggio A, D'Agostino D, Del Rosso A, Romagnoli D, Corsi P, Colicchia M, Barbaresi U, Bianchi L, Giampaoli M, Schiavina R, Palmer K, Del Giudice F, Maggi M, **Ferro M** et al. Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions. *World Journal of Urology*. 2020 Jul 3. doi: 10.1007/s00345-020-03335-4. PMID: 32621027.
- 160)** Luzzago S, Petralia G, Maresca D, Sabatini I, Cordima G, Brescia A, Verweij F, Garelli G, Mistretta FA, Cioffi A, Pricolo P, Alessi S, **Ferro M** et al. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. *Urologic Oncology*. 2020 Dec;38(12):929.e11-929.e19. doi: 10.1016/j.urolonc.2020.05.027. Epub 2020 Jun 26. PMID: 32600928.
- 161)** D'Agostino D, Corsi P, Colicchia M, Romagnoli D, Busetto GM, **Ferro M** et al. The pathological and clinical features of anterior lesions of prostate cancer: Evaluation in a single cohort of patients. *Archivio Italiano di Urologia e Andrologia*. 2020 Jun 23;92(2). doi: 10.4081/aiua.2020.2.102. PMID: 32597109.
- 162)** Mistretta FA, Luzzago S, Molendini LO, **Ferro M** et al. A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. *Cancers (Basel)*. 2020 Jun 10;12(6):1513. doi: 10.3390/cancers12061513. PMID: 32531948.
- 163)** Busetto GM, Porreca A, Del Giudice F, Maggi M, D'Agostino D, Romagnoli D, Musi G, Lucarelli G, Palmer K, Colonna di Paliano A, Muto M, Hurle R, Terracciano D, de Cobelli O, Sciarra A, De Berardinis E, **Ferro M**. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features? *Urologia Internationalis*. 2020;104(7-8):510-522. doi: 10.1159/000509065. Epub 2020 Jun 9. PMID: 32516772.

- 164)** Buonerba C, **Ferro M** et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*. 2020 Jul; 151:102992. Doi:10.1016/j.critrevonc.2020.102992. PMID: 32474391.
- 165)** Mauri G, Mistretta FA, Bonomo G, Camisassi N, Conti A, Vigna PD, **Ferro M** et al. Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center. *Cancers (Basel)*. 2020 May 7;12(5):1183. doi: 10.3390/cancers12051183.
- 166)** Musi G, Cozzi G, Mistretta FA, Tringali VML, Serino A, Jercezek-Fossa BA, Verri E, **Ferro M** et al. Insertion of a testicular prosthesis at the time of radical orchiectomy for testicular cancer is safe in patients who will subsequently undergo chemotherapy or radiotherapy. *Andrologia*. 2020 Jul;52(6):e13613. doi: 10.1111/and.13613.
- 167)** Cozzi G, Musi G, **Ferro M** et al. Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. *Therapeutic Advances in Urology*. 2020 Apr 1; 12:1756287220913386. doi:10.1177/1756287220913386. PMID: 32284736.
- 168)** Bottero D, Fanciullo C, Bonomo G, **Ferro M** et al. Robotic-assisted Laparoscopic Simple Enucleation in a Horseshoe Kidney. A Case Report and Review of the Literature. *Urology*. 2020 Sep; 143:5-10. doi: 10.1016/j.urology.2020.03.034. Epub 2020 Apr 10. PMID: 32283171.
- 169)** Cantiello F, Crocerossa F, Cascini GL, Russo GI, **Ferro M** et al. <sup>64</sup>CuCl<sub>2</sub> PET/CT as a potential new imaging method in prostate cancer: illusion or reality? *Minerva Urologica e Nefrologica*. 2020 Mar 16. doi: 10.23736/S0393-2249.20.03615-2. PMID: 32182228.
- 170)** **Ferro M** et al. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *Urologic Oncology: Seminars and Original Investigations*. 2020 May;38:459-464. doi:10.1016/j.urolonc.2020.02.016. PMID: 32173242.
- 171)** Porpiglia F, Mari A, Amparore D, Fiori C, Antonelli A, Artibani W, Bove P, Brunocilla E, Capitanio U, Da Pozzo L, Di Maida F, Gontero P, Longo N, Marra G, Rocco B, Schiavina R, Simeone C, Siracusano S, Tellini R, Terrone C, Villari D, Ficarra V, Carini M, Minervini A, Altieri V, Berardinelli F, Celia A, Costantini E, Diminutto A, Falsaperla M, **Ferro M** et al. Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project). *Surgical Endoscopy*. 2020 Aug 27. doi: 10.1007/s00464-020-07919-4. PMID: 32856156.
- 172)** Busetto GM, Del Giudice F, Maggi M, Antonini G, D'Agostino D, Romagnoli D, Del Rosso A, Giampaoli M, Corsi P, Palmer K, **Ferro M** et al. Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity. *Aging (Albany NY)*. 2020 Mar 11;12(5):4337-4347. doi: 10.18632/aging.102883. PMID: 32167484.
- 173)** Luzzago S, de Cobelli O, Cozzi G, Peveri G, Bagnardi V, Catellani M, Di Trapani E, Mistretta FA, Pricolo P, Conti A, Alessi S, Marvaso G, **Ferro M** et al. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. *BJU International*. 2020 Jul;126(1):104-113. doi: 10.1111/bju.15048. Epub 2020 Apr 1. PMID: 32150328.
- 174)** Gacci M, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Greco I, Maggi S, Magrini SM, Mirone V, Montironi R, Morgia G, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Russo G, Salonia A, Simonato A, Serni S, Tomasini D, Tubaro A, Zagonel V, Crepaldi G, Conti GN, Gacci M, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini Francolini D, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, deCosimo N, Cristiano O, Rolando DA, Da Pozzo L, D'Agostino D, D'Elia C, Dandrea M, De Angelis P, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli Esposti C, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. *World Journal of Urology*. 2020 Aug 1. doi: 10.1007/s00345-020-03350-5. PMID:32740803.
- 175)** **Ferro M** et al. Beyond PSA: The Role of Prostate Health Index (phi). *International Journal of Molecular Sciences*. 2020 Feb 11;21(4):1184. doi: 10.3390/ijms21041184. PMID: 32053990; PMCID: PMC7072791.
- 176)** Busetto GM, Del Giudice F, Virmani A, Sciarra A, Maggi M, **Ferro M** et al. Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double-blind placebo-controlled trial. *Andrologia*. 2020 Apr;52(3):e13523. doi: 10.1111/and.13523. Epub 2020 Feb 4. PMID: 32017167.
- 177)** Luzzago S, Catellani M, Di Trapani E, Cozzi G, Mistretta FA, Bianchi R, Pricolo P, Conti A, Ancona E, Piacentini N, Alessi S, Renne G, **Ferro M** et al. Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. *Prostate Cancer and Prostatic Diseases*. 2020 Mar;23(1):195. doi: 10.1038/s41391-019-0198-2. Erratum for: *Prostate Cancer Prostatic Dis*. 2020 Mar;23(1):94-101. PMID: 31836874.
- 178)** Veccia A, Antonelli A, Francavilla S, Simeone C, Guruli G, Zargar H, Perdoná S, **Ferro M** et al. Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases. *World Journal of Urology*. 2020 Apr;38(4):845-852. doi: 10.1007/s00345-019-03020-1. Epub 2019 Nov 26. PMID: 31773242.

- 179)** Del Giudice F, Busetto GM, De Berardinis E, Sperduti I, **Ferro M** et al. A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. *Asian Journal of Andrology*. 2020 Jul-Aug;22(4):360-367. doi: 10.4103/aja.aja\_101\_19. PMID: 31621654; PMCID: PMC7406101.
- 180)** Bianchi L, Schiavina R, Borghesi M, Chessa F, Casablanca C, Angiolini A, Ercolino A, Pultrone CV, Mineo Bianchi F, Barbaresi U, Piazza P, Manferrari F, Bertaccini A, Fiorentino M, **Ferro M** et al. Which patients with clinical localized renal mass would achieve the trifecta after partial nephrectomy? The impact of surgical technique. *Minerva Urologica e Nefrologica*. 2020 Jun;72(3):339-349. doi: 10.23736/S0393-2249.19.03485-4. PMID: 31619030.
- 181)** **Ferro M** et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World Journal of Urology*. 2020 Jan;38(1):143-150. doi: 10.1007/s00345-019-02754-2. Epub 2019 Apr 16. PMID: 30993426.
- 182)** Cozzi G, Musi G, Monturano M, Bagnardi V, Frassoni S, Jereczek-Fossa BA, **Ferro M** et al. Sexual function recovery after robot-assisted radical prostatectomy: Outcomes from an Italian referral centre and predicting nomogram. *Andrologia*. 2019 Nov;51(10):e13385. doi: 10.1111/and.13385. Epub 2019 Aug 18. PMID: 31423619.
- 183)** Brad AB, **Ferro M** et al. Particularities and Efficacy of Extracorporeal Shock Wave Lithotripsy in Children. *Urologia Internationalis*. 2019;103(3):318-325. doi: 10.1159/000502101. Epub 2019 Aug 6. PMID: 31387108.
- 184)** Buglione, M, Noale, M, Bruni, A, Antonelli, A, Bertoni, F, Corvo, R, Ricardi, U, Borghetti, P, Maddalo, M, Simeone, C, Mazzeo, E, Porreca, A, Serni, S, Bassi, P, Gacci, M, Mirone, V, Montironi, R, Tubaro, A, Berruti, A, Conti, GN, Maggi, S, Magrini, SM, Triggiani, L, Crepaldi, G, Artibani, W, Bracarda, S, Graziotti, P, Russi, E, Muto, G, Pecoraro, S, Zagonel, V, Alitto, AR, Ambrosi, E, Aristei, C, Bardari, F, Bardoscia, L, Barra, S, Bartoncini, S, Basso, U, Becherini, C, Bellavita, R, Bergamaschi, F, Berlingheri, S, Borghesi, M, Bortolus, R, Borzillo, V, Bosetti, D, Bove, G, Bove, P, Brausi, M, Bruno, G, Brunocilla, E, Buffoli, A, Buttigliero, C, Cacciamani, G, Caldiroli, M, Cardo, G, Carmignani, G, Carrieri, G, Castelli, E, Castrezzati, E, Catalano, G, Cattarino, S, Catucci, F, Cavallini, FD, Ceccarini, O, Celia, A, Chiancone, F, Chini, T, Cianci, C, Cisternino, A, Collura, D, Corbella, F, Corinti, M, Corsi, P, Cortese, F, Corti, L, de Nunzio, C, Cristiano, O, D'angelillo, RM, Da Pozzo, L, D'agostino, D, D'elia, C, Dandrea, M, De Angelis, M, De Angelis, P, De Cobelli, O, De Concilio, B, De Lisa, A, De Luca, S, De Stefani, A, Deantoni, CL, Degli, EC, Destito, A, Detti, B, Di Muzio, N, Di Stasio, A, Di Stefano, C, Di Trapani, D, Difino, G, Falivene, S, Farullo, G, Fedelini, P, Ferrari, I, Ferraù, F, **Ferro, M** et al. Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). *PLoS One*. 2019 Nov 1;14(11):e0224151. doi: 10.1371/journal.pone.0224151. PMID: 31675380.
- 185)** Vartolomei MD, Iwata T, Roth B, Kimura S, Mathieu R, **Ferro M** et al. Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. *World Journal of Urology*. 2019 Nov;37(11):2313-2324. doi: 10.1007/s00345-019-02825-4. Epub 2019 Jun 6. PMID: 31172281.
- 186)** Luzzago S, Catellani M, Di Trapani E, Cozzi G, Mistretta FA, Bianchi R, Pricolo P, Conti A, Ancona E, Piacentini N, Alessi S, Renne G, **Ferro M** et al. Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. *Prostate Cancer and Prostatic Diseases*. 2020 Mar;23(1):94-101. doi: 10.1038/s41391-019-0160-3. Epub 2019 Jun 27. Erratum in: *Prostate Cancer Prostatic Dis*. 2019 Dec 13; PMID: 31249386.
- 187)** Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, **Ferro M**. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non- muscle-invasive Urothelial Bladder Cancer. *European Urology Oncology*. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13. PMID: 31158079.
- 188)** **Ferro M** et al. Dysregulated metabolism: a relevant player in prostate cancer progression and clinical management. *Translational Andrology and Urology*. 2019 Mar;8(Suppl 1):S109-S111. doi: 10.21037/tau.2018.12.05. PMID: 31143683.
- 189)** Lucarelli G, Loizzo D, Franzin R, Battaglia S, **Ferro M** et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. *Expert Review of Molecular Diagnostics*. 2019 May;19(5):397-407. doi: 10.1080/14737159.2019.1607729. Epub 2019 May 2. PMID: 30983433.
- 190)** Lucarelli G, Loizzo D, **Ferro M** et al. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. *Expert Review of Molecular Diagnostics*. 2019 May;19(5):377-387. doi: 10.1080/14737159.2019.1604223. Epub 2019 Apr 24. PMID: 30957583.
- 191)** Antonelli, A, Palumbo, C, Noale, M, Porreca, A, Maggi, S, Simeone, C, Bassi, P, Bertoni, F, Bracarda, S, Buglione, M, Conti, GN, Corvò, R, Gacci, M, Mirone, V, Montironi, R, Triggiani, L, Tubaro, A, Artibani, W, Crepaldi, G, Graziotti, P, Russi, E, Magrini Stefano, M, Muto, G, Pecoraro, S, Ricardi, U, Zagonel, V, Alitto Anna, R, Ambrosi, E, Aristei, C, Barbieri, M, Bardari, F, Bardoscia, L, Barra, S, Bartoncini, S, Basso, U, Becherini, C, Bellavita, R, Bergamaschi, F, Berlingheri, S, Berruti, A, Borghesi, M, Bortolus, R, Borzillo, V, Bosetti, D, Bove, G, Bove, P, Brausi, M, Bruni, A, Bruno, G, Brunocilla, E, Buffoli, A, Buttigliero, C, Cacciamani, G, Caldiroli, M, Cardo, G, Carmignani, G, Carrieri, G, Castelli, E, Castrezzati, E, Catalano, G, Cattarino, S, Catucci, F, Cavallini, FD, Ceccarini, O, Celia, A, Chiancone, F, Chini, T, Cianci, C, Cisternino, A, Collura, D, Corbella, F, Corinti, M, Corsi, P, Cortese, F, Corti, L, de Cosimo, N, Cristiano, O, D'Angelillo, R, Da Pozzo, L, D'agostino, D, D'Elia, C, Dandrea, M, De Angelis, M, De Angelis, P, De Cobelli, O, De Concilio, B, De Lisa, A, De Luca, S, De Stefani, A, Deantoni, CL, Degli Esposti, C, Destito, A, Detti, B, Di Muzio, N, Di Stasio, A, Di Stefano, C, Di Trapani, D, Difino, G, Falivene, S, Farullo, G, Fedelini, P, Ferrari, I, Ferraù, F, **Ferro, M** et al. Impact of Surgical Approach on Patient-Reported Outcomes after

- Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study). *Urologia Internationalis*. 2019;103(1):8-18. doi: 10.1159/000496980. PMID: 30731456.
- 192)** Mir MC, Pavan N, Capitanio U, Antonelli A, Derweesh I, Rodriguez-Faba O, Linares E, Takagi T, Rha KH, Fiori C, Maurer T, Zang C, Mottrie A, Umari P, Long JA, Fiard G, De Nunzio C, Tubaro A, Tracey AT, **Ferro M** et al. Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). *World Journal of Urology*. 2020 Jan;38(1):151-158. doi: 10.1007/s00345-019-02665-2. Epub 2019 Apr 1. PMID: 30937569.
  - 193)** Antonelli A, Veccia A, Pavan N, Mir C, Breda A, Takagi T, Rha KH, Maurer T, Zhang C, Long JA, De Nunzio C, Lima E, **Ferro M** et al. Outcomes of Partial and Radical Nephrectomy in Octogenarians - A Multicenter International Study (Resurge). *Urology*. 2019 Jul;129:139-145. doi: 10.1016/j.urology.2019.03.009. PMID: 30914335.
  - 194)** Antonini G, De Berardinis E, Busetto GM, Del Giudice F, Chung BI, Conti SL, **Ferro M** et al. Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. *International Journal of Impotence Research*. 2020 Jan;32(1):133-139. doi: 10.1038/s41443-019-0125-z. Epub 2019 Feb 11. PMID: 30745567.
  - 195)** Mistretta FA, Galfano A, Di Trapani E, Di Trapani D, Russo A, Secco S, **Ferro M** et al. Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches. *International Brazilian Journal of Urology*. 2019 Mar-Apr;45(2):262-272. doi: 10.1590/S1677-5538.IBJU.2018.0308. PMID: 30676299; PMCID: PMC6541127.
  - 196)** Jereczek-Fossa BA, Maucieri A, Marvaso G, Gandini S, Fodor C, Zerini D, Riva G, Alessandro O, Surgo A, Volpe S, Fanetti G, Arculeo S, Zerella MA, Parisi S, Maisonneuve P, Vavassori A, Cattani F, Cambria R, Garibaldi C, Starzyńska A, Musi G, De Cobelli O, **Ferro M** et al. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external- beam radiotherapy for prostate cancer. *Medical Oncology*. 2018 Nov 27;36(1):9. doi:10.1007/s12032-018-1233-1. PMID:30483899.
  - 197)** Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Lepore Signorile M, Grossi V, Sanese P, Napoli A, Maiorano E, Bianchi C, Perego RA, **Ferro M** et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. *Aging (Albany NY)*. 2018 Dec 11;10(12):3957-3985. doi: 10.18632/aging.101685. PMID: 30538212; PMCID: PMC6326659.
  - 198)** **Ferro M** et al. Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. *World Journal of Urology*. 2019 Jun;37(6):1049-1059. doi: 10.1007/s00345-018-2579-x. Epub 2018 Dec 5. PMID: 30519742.
  - 199)** **Ferro M** et al. Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. *Journal of Cancer*. 2018 Oct 20;9(22):4250-4254. doi: 10.7150/jca.26129. PMID: 30519326; PMCID: PMC6277616.
  - 200)** Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocero F, **Ferro M** et al. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. *Prostate Cancer and Prostatic Diseases*. 2019 May;22(2):206-220. doi: 10.1038/s41391-018-0113-2. Epub 2018 Nov 28. PMID: 30487646.
  - 201)** Gabriele C, Cantiello F, Nicastri A, Crocero F, Russo GI, Cicione A, Vartolomei MD, **Ferro M** et al. High-throughput detection of low abundance sialylated glycoproteins in human serum by TiO 2 enrichment and targeted LC-MS/MS analysis: application to a prostate cancer sample set. *Analytical and Bioanalytical Chemistry*. 2019 Jan;411(3):755-763. doi: 10.1007/s00216-018-1497-5. Epub 2018 Nov 28. PMID: 30483857.
  - 202)** **Ferro M** et al. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. *Urologia Internationalis*. 2019;102(1):43-50. doi: 10.1159/000494259. Epub 2018 Nov 8. PMID: 30408799.
  - 203)** Bove P, Iacovelli V, Tirindelli MC, Bianchi D, Flammia GP, Cipriani C, Ferraro AS, **Ferro M** et al. Endoscopic Intravesical Fibrin Glue Application in the Treatment of Refractory Hemorrhagic Radiation Cystitis: A Single Cohort Pilot Study. *Journal of Endourology*. 2019 Feb;33(2):93-98. doi: 10.1089/end.2018.0028. PMID: 30280911.
  - 204)** Del Giudice F, Busetto GM, Chung BI, Conti SL, **Ferro M** et al. Non-ischemic priapism following recurrent idiopathic ischemic priapism treated successfully with selective arterial embolization and postoperative vacuum therapy before delayed inflatable penile prosthesis placement: A single case report. *IJU Case Reports*. 2018 Sep 20;1(1):13-15. doi: 10.1002/iju5.12019. PMID: 32743355; PMCID: PMC7292072.
  - 205)** Vartolomei MD, Matei DV, Renne G, Tringali VM, Crişan N, Musi G, Mistretta FA, Russo A, Conti A, Cozzi G, Luzzago S, Catellani M, Cioffi A, Cordima G, Bianchi R, Di Trapani E, Serino A, Delor M, Bianco R, Bottero D, **Ferro M** et al. Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. *Minerva Urologica e Nefrologica*. 2019 Feb;71:31-37. doi:10.23736/S0393-2249.18.03006-0.
  - 206)** Lucarelli G, **Ferro M** et al. The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma. *Translational Cancer Research, North America*, 1, aug. 2018. Available at: <<https://tcr.amegroups.com/article/view/23259>>. doi: 10.21037/tcr.2018.08.07
  - 207)** **Ferro M** et al. Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field. *Annals of Surgical Oncology*. 2018 Nov;25(12):3423-3424. doi: 10.

- 208)** Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, **Ferro M** et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. *Prostate Cancer and Prostatic Diseases*. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3.
- 209)** Vartolomei L, **Ferro M** et al. Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients. *Bladder Cancer*. 2018 Jul 30;4(3):319-326. doi: 10.3233/BLC-180181. PMID: 30112443.
- 210)** Vartolomei MD, **Ferro M** et al. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6. PMID: 30077463.
- 211)** **Ferro M** et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World Journal of Urology*. 2019 Mar;37(3):507-514. doi: 10.1007/s00345-018-2397-1. Epub 2018 Jul 10. PMID: 29992381.
- 212)** **Ferro M** et al. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urologia Internationalis*. 2018;101(1):7-15. doi: 10.1159/000490765. Epub 2018 Jul 4. PMID: 29975950.
- 213)** Cantiello F, Crocero F, Russo GI, Gangemi V, **Ferro M** et al. Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. *Clinical Genitourinary Cancer*. 2018 Oct;16(5):385-391. doi: 10.1016/j.clgc.2018.05.014. PMID: 29937067.
- 214)** Cimmino, A., Costa, V., Terracciano, D., **Ferro, M.** Circular RNAs: an emerging type of non-coding RNA and their potential implications in bladder cancer. *Translational Cancer Research, North America*, 1, aug. 2018. doi: <http://dx.doi.org/10.21037/tcr.2018.08.04> Available at: <<https://tcr.amegroups.com/article/view/23483>>.
- 215)** Vartolomei MD, Porav-Hodade D, **Ferro M** et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urologic Oncology*. 2018 Sep;36(9):389-399. doi: 10.1016/j.urolonc.2018.05.014. PMID: 29884342.
- 216)** Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, Eun D, Perdona S, Porter J, Rha KH, Motttrie A, White WM, Schips L, Yang B, Jacobsohn K, Uzzo RG, Challacombe B, **Ferro M** et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). *European Urology*. 2018 Aug;74(2):226-232. doi: 10.1016/j.eururo.2018.05.004. PMID: 29784191.
- 217)** Luzzago S, Musi G, Catellani M, Russo A, Di Trapani E, Mistretta FA, Bianchi R, Cozzi G, Conti A, Pricolo P, **Ferro M** et al. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. *Urologia Internationalis*. 2018;101(1):56-64. doi: 10.1159/000488772. Epub 2018 May 7. PMID: 29734177.
- 218)** Vartolomei MD, Kimura S, **Ferro M** et al. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clinical Epidemiology*. 2018 Apr 17;10:431-444. doi: 10.2147/CLEP.S163668.
- 219)** Balan D, Martha O, Chibelea CB, Tataru S, Voidezan S, Sin A, Matei VD, Vartolomei MD, Lucarelli G, Cioffi A, Del Giudice F, De Berardinis E, Borda A, Busetto GM, **Ferro M** et al. Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. *Medicine (Baltimore)*. 2018 Apr;97(16):e0522. doi: 10.1097/MD.00000000000010522. PMID: 29668641.
- 220)** Cozzi G, Musi G, Bianchi R, Bottero D, Brescia A, Cioffi A, Cordima G, Delor M, Di Trapani E, **Ferro M** et al. Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. *Therapeutic Advances in Urology*. 2017 Oct 9;9(11):241-250. doi: 10.1177/1756287217731449.
- 221)** Vartolomei MD, Kimura S, **Ferro M** et al. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. *World Journal of Urology*. 2018 Jul;36(7):1019-1029. doi: 10.1007/s00345-018-2235-5. Epub 2018 Feb 21. PMID: 29468284.
- 222)** Musi G, Mistretta FA, Marengi C, Russo A, Catellani M, Nazzani S, Conti A, Luzzago S, **Ferro M** et al. Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. *Journal of Endourology*. 2018 Mar;32(3):257-263. doi: 10.1089/end.2017.0915.
- 223)** Musi G, Russo A, Conti A, Mistretta FA, Di Trapani E, Luzzago S, Bianchi R, Renne G, Ramoni S, **Ferro M** et al. Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. *World Journal of Urology*. 2018 Feb;36(2):265-270. doi: 10.1007/s00345-017-2144-z.
- 224)** Porreca, A, Noale, M, Artibani, W, Bassi, PF, Bertoni, F, Bracarda, S, Conti, GN, Corvò, R, Gacci, M, Graziotti, P, Magrini, SM, Mirone, V, Montironi, R, Muto, G, Pecoraro, S, Ricardi, U, Russi, E, Tubaro, A, Zagonel, V, Crepaldi, G, Maggi, S, Alitto, AR, Ambrosi, E, Antonelli, A, Aristei, C, Barbieri, M, Bardari, F, Bardoscia, L, Barra, S, Bartoncini, S, Basso, U, Becherini, C, Bellavita, R, Bergamaschi, F, Berlingheri, S, Berruti, A, Borghesi, M, Bortolus, R, Borzillo, V, Bosetti, D, Bove, G, Bove, P, Maurizio, B, Alessio, B, Giorgio, B, Eugenio, B, Alberto, B, Michela, B, Consuelo, B, Giovanni, C, Michela, C, Giuseppe, C, Giorgio, C, Giuseppe, C, Emanuele, C, Elisabetta, C, Gianpiero, C, Susanna, C, Catucci, F, Dario, CF, Ofelia, C, Antonio, C, Francesco, C, Tommaso, C, Claudia, C, Antonio, C, Devis, C, Franco, C, Matteo, C, Paolo, C, Fiorenza, C, Luigi, C, Cosimo, N, Cristiano, O, D'angelillo, RM, Da Pozzo, L, D'agostino, D, D'elia, C, Dandrea, M, De ngelis, M, De Angelis, P, De Cobelli, O, De Concilio, B, De Lisa, A, De Luca, S, De Stefani, A, Deantoni, CL, Degli, EC, Destito, A, Detti, B, Di Muzio, N, Di Stasio, A, Di Stefano, C, Di Trapani, D, Difino, G, Falivene, S, Farullo, G, Fedelini, P, Ferrari, I, Ferrau, F, **Ferro, M** et al. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. *Health and Quality of Life Outcomes*. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5. PMID: 29898750; PMCID: PMC6001046.

- 225)** Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Carteni G, Federico P, Daniele B, Morelli F, Bellelli T, **Ferro M** et al. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. *European Urology Focus*. 2018 Dec;4(6):874-879. doi: 10.1016/j.euf.2017.03.015. Epub 2017 Apr 8. PMID: 28753882.
- 226)** Vartolomei MD, Matei DV, Renne G, Tringali VM, Crisan N, Musi G, Mistretta FA, Russo A, Cozzi G, Cordima G, Luzzago S, Cioffi A, Di Trapani E, Catellani M, Delor M, Bottero D, Imbimbo C, Mirone V, **Ferro M** et al. Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. *European Urology Focus*. 2019 Jul;5(4):636-641. doi: 10.1016/j.euf.2017.10.005. Epub 2017 Oct 27. PMID: 29111154.
- 227)** Gacci M, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Lilia B, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini FD, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Cosimo N, Cristiano O, D'Angelillo Rolando M, Da Pozzo L, D'Agostino D, D'Andrea D, Dandrea M, De Angelis M, De Angelis P, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli Esposti C, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. *Eur Urol Focus*. 2017 Oct;3(4-5):321-324. doi: 10.1016/j.euf.2017.10.009. PMID: 29146557.
- 228)** Matei DV, Zanagnolo V, Vartolomei MD, Crisan N, **Ferro M** et al. Robot-Assisted Vesico-Vaginal Fistula Repair: Our Technique and Review of the Literature. *Urologia Internationalis*. 2017;99(2):137-142. doi: 10.1159/000475887. PMID: 28743109.
- 229)** Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Carteni G, Daniele B, Morelli F, **Ferro M** et al. PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. *Medicine (Baltimore)*. 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817. PMID: 28614217.
- 230)** Antonini G, Busetto GM, Del Giudice F, **Ferro M** et al. Distal Corporal Anchoring Stitch: A Technique to Address Distal Corporal Crossovers and Impending Lateral Extrusions of a Penile Prosthesis. *Journal of Sexual Medicine*. 2017 Jun;14(6):767-773. doi: 10.1016/j.jsxm.2017.04.669. PMID: 28583338.
- 231)** **Ferro M** et al. Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS). *International Journal of Molecular Sciences*. 2017 May 27;18(6):1146. doi: 10.3390/ijms18061146. PMID: 28555004.
- 232)** Matei DV, Vartolomei MD, Musi G, Renne G, Tringali VML, Mistretta FA, Delor M, Russo A, Cioffi A, Bianchi R, Cozzi G, Di Trapani E, Bottero D, Cordima G, Lucarelli G, **Ferro M** et al. Outcomes of robot-assisted simple enucleation of renal masses: A single European center experience. *Medicine (Baltimore)*. 2017 May;96(18):e6771. doi: 10.1097/MD.0000000000006771. PMID: 28471972.
- 233)** Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G, Alitto AR, Ambrosi E, Antonelli A, Aristei C, Barbieri M, Bardari F, Bardoscia L, Barra S, Bartoncini S, Basso U, Becherini C, Bellavita R, Bergamaschi F, Berlingheri S, Berruti A, Borghesi M, Bortolus R, Borzillo V, Bosetti D, Bove G, Bove P, Brausi M, Bruni A, Bruno G, Brunocilla E, Buffoli A, Buglione M, Buttigliero C, Cacciamani G, Caldiroli M, Cardo G, Carmignani G, Carrieri G, Castelli E, Castrezzati E, Catalano G, Cattarino S, Catucci F, Cavallini Francolini D, Ceccarini O, Celia A, Chiancone F, Chini T, Cianci C, Cisternino A, Collura D, Corbella F, Corinti M, Corsi P, Cortese F, Corti L, de Nunzio C, Cristiano O, D'Angelillo R, Da Pozzo L, D'agostino D, D'Andrea D, Dandrea M, De Angelis M, De Cobelli O, De Concilio B, De Lisa A, De Luca S, De Stefani A, Deantoni CL, Degli Esposti C, Destito A, Detti B, Di Muzio N, Di Stasio A, Di Stefano C, Di Trapani D, Difino G, Falivene S, Farullo G, Fedelini P, Ferrari I, Ferrau F, **Ferro M** et al. Pros-IT CNR: an Italian prostate cancer monitoring project. *Aging Clinical and Experimental Research*. 2017 Apr;29(2):165-172. doi:10.1007/s40520-017-0735-6. Epub 2017 Feb 24. PMID: 28236267.
- 234)** Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, **Ferro M** et al. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. *Urology*. 2017 Aug;106:139-145. doi: 10.1016/j.urology.2017.04.019. Epub 2017 Apr 21. PMID: 28438628.
- 235)** Terracciano D, **Ferro M** et al. Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. *Translational Research*. 2017 Jun;184:108-117. doi: 10.1016/j.trsl.2017.03.005. Epub 2017 Apr 7. PMID: 28438520.
- 236)** Lucarelli G, Rutigliano M, **Ferro M** et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. *Urologic Oncology*. 2017 Jul;35(7):461.e15-461.e27. doi: 10.1016/j.urolonc.2017.02.011. Epub 2017 Mar 28. PMID: 28359744.
- 237)** Pavan N, Derweesh IH, Mir CM, Novara G, Hampton LJ, **Ferro M** et al. Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4 Cm) Kidney Tumors: Systematic Review and Meta- Analysis. *Annals of Surgical Oncology*. 2017 Aug;24(8):2420-2428. doi: 10.1245/s10434-017-5831-5. Epub 2017 Mar 16. PMID: 28303428.

- 238)** Matei DV, Vartolomei MD, Renne G, Tringali VML, Russo A, Bianchi R, Cozzi G, Bottero D, Musi G, Mazzarol G, **Ferro M** et al. Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn? *Clinical Genitourinary Cancer*. 2017 Aug;15(4):e689-e696. doi:10.1016/j.clgc.2017.01.012. PMID: 28216275.
- 239)** Busetto GM, **Ferro M** et al. The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*. 2017 Aug;15(4):e661-e666. doi: 10.1016/j.clgc.2017.01.011. Epub 2017 Jan 18. PMID: 28188046.
- 240)** Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, **Ferro M** et al. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. *Clinical Genitourinary Cancer*. 2017 Aug;15(4):e623-e632. doi: 10.1016/j.clgc.2017.01.004. Epub 2017 Jan 11. PMID: 28185875.
- 241)** Buonerba C, Di Lorenzo G, Pond G, Carteni G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, **Ferro M** et al. Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. *Frontiers in Pharmacology*. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. PMID: 28066240; PMCID: PMC5168461.
- 242)** Buonerba C, Di Lorenzo G, Calderoni G, **Ferro M** et al. The evolving landscape in advanced penile cancer. *Future Science OA*. 2015 Nov 1;1(3):FSO9. doi: 10.4155/fso.15.7. PMID: 28031884; PMCID: PMC5137911.
- 243)** Terreri S, Durso M, Colonna V, Romanelli A, Terracciano D, **Ferro M** et al. New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. *Genes (Basel)*. 2016 Dec 14;7(12):127. doi: 10.3390/genes7120127. PMID: 27983635; PMCID: PMC5192503.
- 244)** **Ferro M** et al. Virtue male sling for post-prostatectomy stress incontinence: a prospective evaluation and mid-term outcomes. *BJU International*. 2017 Mar;119(3):482-488. doi: 10.1111/bju.13672. PMID: 27696622.
- 245)** Falzarano SM, **Ferro M** et al. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. *Minerva Urologica e Nefrologica*. 2015 Sep;67(3):211-31. Epub 2015 Jun 9. PMID: 26054411.
- 246)** **Ferro M** et al. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. *Oncotarget*. 2017 Mar 14;8(11):18424-18434. doi: 10.18632/oncotarget.12906. PMID: 27793023; PMCID: PMC5392340.
- 247)** Lucarelli G, **Ferro M** et al. Multi-omics approach reveals the secrets of metabolism of clear cell-renal cell carcinoma. *Translational Andrology and Urology*. 2016 Oct;5(5):801-803. doi: 10.21037/tau.2016.06.12. PMID: 27785441.
- 248)** Bianchi R, Cozzi G, Petralia G, Alessi S, Renne G, Bottero D, Brescia A, Cioffi A, Cordima G, **Ferro M** et al. Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. *Medicine (Baltimore)*. 2016 Oct;95(40):e4519. doi: 10.1097/MD.0000000000004519. PMID: 27749525.
- 249)** **Ferro M** et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. *Future Oncology*. 2017 Feb;13(3):285-293. doi: 10.2217/fon-2016-0217. Epub 2016 Sep 14. PMID: 27624840; PMCID: PMC5619099.
- 250)** Gerardi MA, Jereczek-Fossa BA, Zerini D, Surgo A, Dicuonzo S, Spoto R, Fodor C, Verri E, Rocca MC, Nolè F, Muto M, **Ferro M** et al. Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. *Ecancermedicalscience*. 2016 Jul 14;10:657. doi: 10.3332/ecancer.2016.657. PMID: 27563352.
- 251)** Di Lorenzo G, De Placido S, Pagliuca M, **Ferro M** et al. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. *Expert Opinion on Biological Therapy*. 2016 Nov;16(11):1387-1401. doi: 10.1080/14712598.2016.1216964. Epub 2016 Aug 5. PMID:27463642.
- 252)** Almeida GL, Petralia G, **Ferro M** et al. Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria. *Urologia Internationalis*. 2016;96(4):459-69. doi: 10.1159/000444197. Erratum in: *Urol Int*. ;97(3):372. PMID: 27045167.
- 253)** Olivieri M, **Ferro M** et al. Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. *Oncotarget*. 2016 Apr 12;7(15):20636-54. doi: 10.18632/oncotarget.7833. PMID: 26943042.
- 254)** Pavan N, Autorino R, Lee H, Porpiglia F, Sun Y, Greco F, Jeff Chueh S, Han DH, Cindolo L, **Ferro M** et al. Impact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology. *World Journal of Urology*. 2016 Oct;34(10):1473-9. doi: 10.1007/s00345-016-1791-9. Epub 2016 Feb 29. PMID: 26923920.
- 255)** **Ferro M** et al. Biomarkers in localized prostate cancer. *Future Oncology*. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15. PMID: 26768791; PMCID: PMC5549774.
- 256)** Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, **Ferro M** et al. Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. *Medicine (Baltimore)*. 2015 Dec;94(51):e2297. doi: 10.1097/MD.0000000000002297. PMID: 26705213; PMCID: PMC4697979.
- 257)** Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S, Bufo P, Maiorano E, Ribatti D, Ranieri E, Gigante M, Gesualdo L, **Ferro M** et al. Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. *Medicine (Baltimore)*. 2015 Nov;94(46):e2117. doi: 10.1097/MD.0000000000002117. PMID: 26579829; PMCID: PMC4652838.

- 258)** Ferro M et al. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. *Medicine (Baltimore)*. 2015 Oct;94(42):e1861. doi:10.1097/MD.0000000000001861. PMID: 26496339; PMCID: PMC4620818.
- 259)** de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Bottero D, Cioffi A, Jereczek-Fossa B, Petralia G, Cordima G, Almeida GL, Lucarelli G, Buonerba C, Matei DV, Renne G, Di Lorenzo G, **Ferro M**. Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. *PLoS One*. 2015 Oct 7;10(10):e0139696. doi: 10.1371/journal.pone.0139696. PMID: 26444548; PMCID: PMC4596627.
- 260)** Giovannone R, Busetto GM, Antonini G, De Cobelli O, **Ferro M** et al. Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction: International Index of Erectile Function (IIEF) and Penile Doppler Ultrasound Correlation With Plasma Levels of Homocysteine. *Medicine (Baltimore)*. 2015 Sep;94(39):e1556. doi: 10.1097/MD.0000000000001556. PMID: 26426624; PMCID: PMC4616856.
- 261)** De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, **Ferro M**. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. *Future Oncology*. 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. PMID: 26381851.
- 262)** Cantiello F, Russo GI, Cicione A, **Ferro M** et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. *World Journal of Urology*. 2016 Apr;34(4):485-93. doi: 10.1007/s00345-015-1643-z. Epub 2015 Jul 21. PMID: 26194612.
- 263)** Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, **Ferro M** et al. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. *Expert Review of Molecular Diagnostics*. 2015;15(9):1211-24. doi: 10.1586/14737159.2015.1069711. Epub 2015 Jul 15. PMID: 26174441.
- 264)** Autorino R, Zargar H, Mariano MB, Sanchez-Salas R, Sotelo RJ, Chlosta PL, Castillo O, Matei DV, Celia A, Koc G, Vora A, Aron M, Parsons JK, Pini G, Jensen JC, Sutherland D, Cathelineau X, Nuñez Bragayrac LA, Varkarakis IM, Amparore D, **Ferro M** et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. *European Urology*. 2015 Jul;68(1):86-94. doi: 10.1016/j.eururo.2014.11.044. Epub 2014 Dec 4. PMID: 25484140.
- 265)** Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R, Perdonà S, De Cobelli O, **Ferro M** et al. The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. *International Journal of Oncology*. 2015 Aug;47(2):527-34. doi: 10.3892/ijo.2015.3038. Epub 2015 Jun 8. PMID: 26058426.
- 266)** Buonerba C, **Ferro M** et al. How can we improve prognostic models in renal cell carcinoma? *Expert Opinion on Pharmacotherapy*. 2015 Jun;16(9):1281-3. doi: 10.1517/14656566.2015.1046838. PMID: 26001179.
- 267)** de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Galasso G, Cioffi A, Cordima G, Musi G, Damiano R, Cantiello F, Detti S, Victor Matei D, Bottero D, Renne G, **Ferro M**. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. *Urologic Oncology*. 2015 May;33(5):201.e1-8. doi: 10.1016/j.urolonc.2015.02.004. PMID: 25791753.
- 268)** Matei DV, **Ferro M** et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. *Urologia Internationalis*. 2015;94:373-82. doi: 10.1159/000371893. PMID: 25765848.
- 269)** **Ferro M** et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. *Anticancer Research*. 2015 Feb;35(2):1017-23. PMID: 25667489.
- 270)** Cantiello F, Russo GI, **Ferro M** et al. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. *Urologic Oncology*. 2015 Apr;33(4):163.e15-23. doi: 10.1016/j.urolonc.2014.12.002. Epub 2015 Jan 6. PMID: 25575715.
- 271)** Di Lorenzo G, Buonerba C, **Ferro M** et al. The epidermal growth factor receptors as biological targets in penile cancer. *Expert Opinion on Biological Therapy*. 2015 Apr;15(4):473-6. doi: 10.1517/14712598.2015.993377. Epub 2014 Dec 11. PMID: 25496291.
- 272)** Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpati GD, **Ferro M** et al. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. *Future Oncology*. 2014 Jun;10(8):1353-60. doi: 10.2217/fon.14.71. PMID: 25052746.
- 273)** Busetto GM, Giovannone R, **Ferro M** et al. Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). *BMC Urology*. 2014 Jul 19;14:53. doi: 10.1186/1471-2490-14-53. PMID: 25038794.
- 274)** Bruzzese D, Mazzarella C, **Ferro M** et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. *Translational Research*. 2014 Dec;164:444-51. doi:10.1016/j.trsl.2014.06.006. PMID: 25035153.
- 275)** Maresca L, D'Agostino M, Castaldo L, Vitelli A, Mancini M, Torella G, Lucci R, Albano G, Del Forno D, **Ferro M** et al. Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. *Monaldi Arch Chest Dis*. 2013 Dec;80:177-83. doi: 10.4081/monaldi.2013.5234. PMID: 25087294.

- 276)** Cantiello F, Cicione A, Autorino R, Salonia A, Briganti A, **Ferro M** et al. Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. *World Journal of Urology*. 2014 Apr;32(2):559-64. doi: 10.1007/s00345-013-1147-7. PMID: 23942944.
- 277)** **Ferro M** et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. *PLoS One*. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. PMID: 23861782; PMCID: PMC3701535.
- 278)** Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, **Ferro M** et al. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. *Journal of Translational Medicine*. 2013 Jul 2;11:161. doi: 10.1186/1479-5876-11-161. PMID: 23819610.
- 279)** Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, **Ferro M** et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. *Future Oncology*. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39. PMID: 23718309.
- 280)** Montanaro V, Di Girolamo A, **Ferro M** et al. Come attuare il follow-up in rapporto alla categoria di rischio [How to apply follow-up in relation to risk group]. *Urologia*. 2013;80 Suppl 21:42-7. Italian. doi: 10.5301/RU.2013.10864. Epub 2013 Mar 22. PMID: 23559135.
- 281)** Buonerba C, Caraglia M, Maligni S, Perri F, Bosso D, Federico P, **Ferro M** et al. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? *Expert Opinion on Biological Therapy*. 2013 Feb;13(2):149-51. doi: 10.1517/14712598.2012.756470. Epub 2012 Dec 25. PMID: 23265605.
- 282)** Di Lorenzo G, D'Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, **Ferro M** et al. Peg- filgrastim and cabazitaxel in prostate cancer patients. *Anti-cancer Drugs*. 2013 Jan;24(1):84-9. doi:10.1097/CAD.0b013e32835a56bc. PMID: 23044721.
- 283)** Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, **Ferro M** et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. *BJU International*. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. PMID: 22958571.
- 284)** Terracciano D, Bruzzese D, **Ferro M** et al. Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. *Oncology Letters*. 2011 Sep 1;2(5):861-864. doi: 10.3892/ol.2011.337. Epub 2011 Jul 4. PMID: 22866141; PMCID: PMC3408018.
- 285)** Perdonà S, Bruzzese D, **Ferro M** et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. *Prostate*. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20. PMID: 22821756.
- 286)** **Ferro M** et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. *Clinica Chimica Acta*. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20. PMID: 22542564.
- 287)** Di Lorenzo G, **Ferro M** et al. How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. *Expert Review of Anticancer Therapy*. 2012 Mar;12(3):331-3. doi: 10.1586/era.11.215. PMID: 22369324.
- 288)** Di Lorenzo G, **Ferro M**, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. *BJU International*. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. PMID: 22177289.
- 289)** **Ferro M** et al. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. *Oncology Reports*. 2012 Feb;27(2):409-15. doi: 10.3892/or.2011.1526. Epub 2011 Oct 31. PMID: 22052369.
- 290)** Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, Fusco R, Ronza FM, Caraglia M, **Ferro M** et al. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. *Urologic Oncology*. 2013 Aug;31(6):761-5. doi: 10.1016/j.urolonc.2011.07.010. PMID: 21906966.
- 291)** Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, **Ferro M** et al. Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. *Cancer Chemotherapy and Pharmacology* 67,1463(2011). <https://doi.org/10.1007/s00280-011-1626-8>
- 292)** Di Lorenzo G, Federico P, Buonerba C, Longo N, Carteni G, Autorino R, Perdonà S, **Ferro M** et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. *European Urology*. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22. PMID: 21871710.
- 293)** Terracciano D, Bruzzese D, **Ferro M** et al. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading. *Prostate*. 2012 Jan;72:100-7. doi:10.1002/pros.21411. PMID:21520165.
- 294)** Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, **Ferro M** et al. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. *Cancer Chemotherapy and Pharmacology*. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Erratum in: *Cancer Chemother Pharmacol*. 2011 Jun;67(6):1463. PMID: 21365219.
- 295)** Capasso R, Aviello G, Borrelli F, Romano B, **Ferro M** et al. Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. *Urology*. 2011 Apr;77(4):1006.e9-1006.e15. doi: 10.1016/j.urology.2010.12.006. Epub 2011 Feb 18. PMID: 21310467.
- 296)** Buonerba C, **Ferro M** et al. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. *Expert Review of Anticancer Therapy*. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. PMID: 21166508.

- 297)** Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, **Ferro M** et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. *BJU International*. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x. PMID: 20590545.
- 298)** Terracciano D, Mazzearella C, Di Carlo A, Mariano A, **Ferro M** et al. Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. *Oncology Reports*. 2010 Jul;24(1):213-7. doi: 10.3892/or\_00000848. PMID: 20514464.
- 299)** Di Carlo A, Mariano A, Terracciano D, **Ferro M** et al. Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. *Oncology Reports*. 2010 Jul;24(1):3-8. doi: 10.3892/or\_00000821. PMID: 20514437.
- 300)** Di Lorenzo G, Carteni G, Autorino R, Gonnella A, Perdonà S, **Ferro M** et al. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. *Anti-cancer Drugs*. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293. PMID: 19262371.

#### ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI CENTRI O GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI O PARTECIPAZIONE AGLI STESSI

(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)

- **CR-UK/YCR Sheffield Cancer Research Centre -Biochemical pathways in human urogenital tumours: international partnership** - dal 01-01-2005 al 06-11-2016
- **M.I.R.R.O.R. (Multicenter italian report on radical prostatectomy: Outcome and Research) della fondazione L.U.N.A.** - Sub Investigator: Matteo Ferro - dal 01-01-2010 al 21-09-2016
- **Saarland University-Clinic of Urology and Pediatric Urology -D-66421 Homburg-Saar/Germany-** The study of biochemical pathways and clinical markers regulated in prostate adenocarcinoma: international partnership. - dal 29-08-2012 al 04-11-2016
- **ROL (Rete Oncologica Lombarda) Tumore della Vescica - Bladder Sparing** - Coinvestigator: Matteo Ferro - dal 16-12-2014 ad oggi
- **International partnership on: FASCIN1 an eventual new biomarker in Prostate Cancer-** George Emil Palade University of Medicine, Pharmacy, Sciences and Technology - Târgu Mureș Romania - dal 22-12-2015 ad oggi
- **International partnership on: Long noncoding RNAs containing ultra-conserved genomic region 8 as putative biomarker for bladder cancer detection and prognosis. Depts. of Translational Molecular Pathology & Leukemia** - Co-Director, The RNA Interference and Non-coding RNA Center gcalin@mdanderson.org - Office: 713-792-5461 - 1901 East Rd., Unit 1950 - Houston, Texas 77054 - dal 01-01-2017 ad oggi
- **National Partnership on: Studio LANZA - Conta delle cellule tumorali circolanti nei pazienti con tumore alla prostata che ricevono enzalutamide** -Dipartimento di Medicina di Precisione - Università Vanvitelli (Caserta) - dal 02-07-2017 ad oggi
- **National Partnership on: CABazitaxel con o senza prednisone in pazienti con tumore prostatico metastatico CAstrazione REsistente (mCRPC) che progredivano durante o dopo una precedente chemioterapia basata su docetaxel: uno studio multicentrico, prospettico, a due bracci, open label, fase II** - Università Vanvitelli (Caserta) - dal 12-07-2017 ad oggi
- **Evaluation of p2Psa and Phi for detection of Prostate cancer at the initial biopsy for the prostate cancer aggressiveness stratification** - Grantor: Beckman Coulter - Ruolo: Principal investigator dal 01-01-2012 al 01-01-2014
- **Virtue® Male Sling European Study** - Ruolo: Investigator - dal 18-12-2014 al 16-07-2018
- **EFFECT OF RADIATION HISTORY ON CONTINENCE OUTCOME AFTER QUADRANTIC MALE SLING (VIRTUE) PLACEMENT IN PATIENTS WITH POST-PROSTATECTOMY INCONTINENCE-** Italian Register Sponsor Protocol: Sling Maschile VIRTUE - Principal Investigator: Ferro Matteo - dal 01-01-2019 ad oggi
- **The impact of SelectedMDx on prediction Aggressive prostate Cancer pathology in Patients Undergoing Radical prostatectomy** - Qualifica: P.I. - Dal 24-05-2019 ad oggi
- **PROGETTI DI RICERCA di Ateneo AFFERENTI ALLA QUOTA DELLO STANZIAMENTO DI BILANCIO (EX 60%) Università degli Studi di Salerno - ANNO 2013 PROGETTO**

- INDIVIDUALE Codice ORSA132171** - Dottorando di ricerca: "Panel di marcatori sierici preoperatori per la definizione dell'aggressività del cancro della prostata" - durata 12 mesi
- **PROGETTI DI RICERCA di Ateneo AFFERENTI ALLA QUOTA DELLO STANZIAMENTO DI BILANCIO (EX 60%) Università degli Studi di Salerno - ANNO 2015 PROGETTO INDIVIDUALE Codice ORSA152755** - Titolo della ricerca: "RUOLO DEL METABOLISMO DEL BISFENOLO A NELL'IPERTROFIA PROSTATICA BENIGNA (IPB)" - Qualifica: 8.2 Dipendenti di altre amministrazioni pubbliche, di enti pubblici o privati, di imprese: Ferro Matteo - durata 12 mesi
  - **PROGETTI DI RICERCA di Ateneo AFFERENTI ALLA QUOTA DELLO STANZIAMENTO DI BILANCIO (EX 60%) Università degli Studi di Salerno - ANNO 2015 PROGETTO INDIVIDUALE Codice ORSA141731** - Titolo della ricerca: "RUOLO DEL METABOLISMO DEL BISFENOLO A NELL'IPERTROFIA PROSTATICA BENIGNA (IPB)" - (8.2 Dipendenti di altre amministrazioni pubbliche, di enti pubblici o privati, di imprese): Ferro Matteo - durata 12 mesi
  - **Horizon 2020 Grant Agreement number: 732515 – SMARTsurg – H2020-ICT-2016-2017/H2020-ICT-2016-1-** Key Personnel: Ferro Matteo (European Institute of Oncology) - dal 01-01-2016 a oggi.
  - **Progetto "TENPRO prostate: indice di rischio per la diagnosi personalizzata di cancro della prostata"** finanziato dalla Ricerca di Ateneo - 2020 Linea B - Università degli studi di Napoli Federico II
  - **Progetto SIU "WAITING4" - Società Italiana di Urologia** - Panel Esperti 29-06-2023

**ATTIVITÀ QUALI LA DIREZIONE O LA PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE SCIENTIFICHE**  
(per ciascuna voce inserire anno, ruolo, rivista scientifica, ecc.)

**Associate Editor:** Frontiers Oncology (Genitourinary Oncology) 16.07.20.  
**Member of editorial Board:** Diagnostics dal 01-01-2020; Experimental and Therapeutic Medicine dal 2021; Clinical Genitourinary Cancer dal 06-02-2023.  
**Academic Editor:** Medicine Baltimore dal 04-08-2020.  
**Review Editor:** Frontiers in Oncology dal 15-11-2015.  
**Reviewer:** Clinical Genitourinary Cancer dal 01-01-2014; Andrologia dal 01-01-2014; Medicine Baltimore dal 01-01-2014; World Journal of Urology dal 01-01-2014; International Journal of Urology dal 01-01-2014; Urologic Oncology: Seminars and Original Investigations dal 01-01-2015; Oncology Reports dal 01-01-2015; Asian Journal of Urology dal 01-01-2015; Future Oncology dal 01-01-2015; Future Medicine dal 01-01-2016; Annals of Infectious Disease and Epidemiology dal 01-01-2016; Oncology Letters dal 01-01-2016; Expert Review of Precision Medicine and Drug Development dal 01-01-2016; Journal of Occupational Medicine and Toxicology dal 02-04-2016; Plos one Reviewer dal 01-01-2016; Asian Journal of Andrology dal 01-09-2016; Disease Markers dal 01-01-2017; Urology Updates OPR Science dal 01-01-2017; Oncotarget dal 01-01-2017; Ecancer dal 01-01-2017; OncoTargets and Therapy 01-01-2017; BMC Cancer dal 01-01-2017; Evidence-Based Complementary and Alternative Medicine dal 01-02-2017; Prostate cancer and Prostatic disease dal 05-03-2017; Romanian Journal of Laboratory Medicine dal 01-10-2017; Translational Cancer Research dal 01-01-2018; European Urology Focus dal 01-04-2018; Research and Reports in Urology dal 01-05-2018; Cancer Management and Research dal 01-06-2018; Translational Andrology and Urology 26-11-2018; The Journal of Clinical Medicine dal 01-12-2018; The Journal of Urology dal 20-12-2018; Surgical Oncology dal 01-10-2020; Cancer Biomarkers dal 01-10-2020; Mini-invasive Surgery dal 10-10-2020; Journal of Clinical Nephrology and Research dal 17-10-2020; Journal of Oncology dal 19-10-2020; Therapeutic Advances in Urology dal 01-03-2018; Biomarkers in Medicine Dal 03-04-2017; BJU International dal 02-04-2019; Investigative and Clinical Urology dal 04-06-2019; Journal of Diabetes 01-03-2019; Cancer Control dal 01-02-2019; Turkish Journal of Urology dal 02-03-2020; Cancer Medicine dal 03-01-2019; Cancers dal 01-01-2020; International Journal of Molecular Sciences dal 01-02-2020; Acta Oncologica dal 01-01-2020; Cellular Oncology dal 2020; Future Science OA dal 01-01-2020; International Journal of Environmental Research and Public Health dal 02-03-2019; Journal of Clinical Medicine dal 01-01-2020; Molecular Biology Reports dal 2020; Technology in Cancer Research & Treatment dal 04-05-2020; World Journal of Surgical Oncology dal 01-02-2019; The Revista da Associação Médica Brasileira dal 01-07-2023.

## PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

- 1) AKT ACTIVATION IS INVOLVED IN OLEATE-INDUCED DOCETAXEL RESISTANCE IN ANDROGEN-INDEPENDENT PROSTATE CANCER CELLS ANTICANCER RESEARCH- Volume 34-Numero 5-Pag.2615-2615 -Premio Società Italiana di Urologia Oncologica 2014-22-24 Giugno: Miglior Abstract: Section ricerca di base 24-06-2014
- 2) Acknowledgment Peer Reviewers of 2015 - International Journal of Urology: Matteo Ferro 01-12-2015
- 3) Acknowledgment Peer Reviewers of 2017 International Journal of Urology: Matteo Ferro 04-12-2017
- 4) Asian Journal of Andrology Outstanding Reviewer Award: Best 20 peer reviewers - Matteo Ferro 01-01-2018
- 5) "TENPROProstate: biochip per il dosaggio di pannelli di biomarcatori prognostici utili alla scelta della strategia terapeutica da adottare in pazienti con diagnosi di tumore prostatico" -Premio InnovaSIBioC: Business Idea -Ruolo nel Team di ricerca: Gestione Clinica -Ferro Matteo -10-04-2018
- 6) Finalisti della Call for Ideas - Team ELICADEA: Bioupper 2018 - Milano
- 7) Finalisti Top Ten : EIT Health Jumpstarter 2019 (riconoscimento internazionale )- Vincitrice del Best Presentation Award al BioItaly Roadshow, Sala Auditorium del Ceinge, Napoli 06-02-2019
- 8) Top Ten Roadshow BioItaly 2019 - Napoli
- 9) Vincitore del 3° Premio Start Cup Campania 2019- componente gruppo ELICADEA Premio c/o il COINOR - Università degli Studi di Napoli Federico II -C.so Umberto I, 40 - 80138 Napoli. 03-12-2019
- 10) "Reviewer of the Month January 2021" - Investigative and Clinical Urology - 05-02-2021
- 11) Inclusione nella "World's Top 2% Most-cited Scientists by Stanford University Ranking 2022" -Rank: 178.565 - 10-10-2022
- 12) Vincitore 1° premio Startcup Campania 2022 con il progetto URiN-BB (test urinario per la diagnosi precoce del cancro della vescica), Palazzo comunale, Procida, 24 Ottobre 2022
- 13) Top Italian Scientists in Clinical Sciences - Rank 835 - Area: Urology

## PARTECIPAZIONE IN QUALITÀ DI RELATORE A CONGRESSI E CONVEGNI DI INTERESSE INTERNAZIONALE

### Faculty o Presidenza:

- 1.Napoli, OPEN QUESTIONS IN PRACTICAL UROLOGY Segreteria scientifica dal 01-12-2011 al 02-12-2011
- 2.XXI Congresso Nazionale SIUrO -Napoli Società Italiana di Urologia Oncologica (SIUrO) dal 22-06-2011 al 24-06-2011
- 3.Athens - Forum on Robotic Surgery in Urology Obesity and Prostate cancer (1st edition) dal 14-02-2014 al 15-02-2014
- 4.CONVEGNO MACRO REGIONALE-SIURO Basilicata - Campania - Calabria CLINICAL CASE CONTEST dal 17-10-2014 al 18-10-2014
- 5.Milano, Prostata ed oltre dal 18-06-2015 al 19-06-2015
- 6.Roma 15° Congresso nazionale IEA dal 25-02-2016 al 27-02-2016
- 7.Athens Forum on Robotic Surgery in Urology (3rd edition) dal 27-05-2016 al 28-05-2016
- 8.Milano, IEO-MRI in Prostate Cancer dal 21-02-2019 al 21-02-2019
- 9.Napoli, 2nd UrOnews National Meeting Nuove strategie diagnostiche e terapeutiche in uro-oncologia Enucleazione di neoformazione renale robot-assistita dal 20-06-2019 al 21-06-2019
- 10.Milano, Corso di Chirurgia: CORREZIONE DELL'INCONTINENZA URINARIA MASCHILE CON SLING VIRTUE dal 12-07-2019 al 12-07-2019
- 11.Milano Corso di Chirurgia: CORREZIONE DELL'INCONTINENZA URINARIA MASCHILE CON SLING VIRTUE Live surgery -Impianto Sling Virtue - 30-09-2019
- 12.Milano Corso di Chirurgia: CORREZIONE DELL'INCONTINENZA URINARIA MASCHILE CON SLING VIRTUE - Impianto Sling Virtue - 11-11-2019
- 13.Milano Corso di Chirurgia: CORREZIONE DELL'INCONTINENZA URINARIA MASCHILE CON SLING VIRTUE dal 03-02-2020 al 03-02-2020
- 14.XI CONGRESSO NAZIONALE SIUT -SIUT-webinar/virtuale -TAVOLA ROTONDA: Il Tumore Della Prostata Nell'ambulatorio Territoriale dal 26-11-2021 al 27-11-2021

- **15.Napoli - III° UrOnews National Meeting Nuove strategie diagnostiche e terapeutiche in uro-oncologia - Semi-live: Prostatectomia radicale trans perineale robot assistita dal 12-04-2022 al 13-04-2022**
- **16.Bari - I Masterclass sulle attuali tecnologie chirurgiche nel trattamento dei LUTS secondari ad IPB- TRATTAMENTO DELLA IPB SEVERA: FACE TO FACE dal 06-06-2022 al 07-06-2022**
- **17.Napoli - IV UrOnews National Meeting Nuove strategie diagnostiche e terapeutiche in uro-oncologia - III SESSIONE PROSTATA -Live Surgery dal 18-04-2023 al 19-04-2023**
- **18.Riccione - 95° Congresso SIU 2022 -Sessione MISTA: PROSTATECTOMIA RADICALE: TECNICHE CHIRURGICHE 17-10-2022**
- **19.Roma - XXX CONGRESSO NAZIONALE Auro -UPDATE Nuovi approcci integrati al carcinoma prostatico metastatico dal 11-05-2023 al 13-05-2023**
- **20.Milano- XXII Congresso Nazionale IEA Lectures' corner 4 dal 11-05-2023 al 13-05-2023**

## Relatore:

- **21.Milano - XIX Congresso Nazionale Società Italiana di Urologia Oncologica.**
  - Poster presentation 110 - IPOREGOLAZIONE DI CYR 61 IN LINEE CELLULARI DI ADENOCARCINOMA PROSTATICO TRATTATE CON ACIDO ZOLEDRONICO(ZOL) E DOCETAXEL(DTX): UNA NUOVA STRATEGIA TERAPEUTICA
  - Poster presentation 140 - IMPATTO DELLA RIABILITAZIONE URINARIA PRE-OPERATORIA SULLA RIPRESA DELLA CONTINENZA URINARIA POST-PROSTATECTOMIA RADICALE RETRO PUBICA: NOSTRA
  - Poster presentation - FORME MOLECOLARI DELL'ANTIGENE PROSTATICO SPECIFICO (PSA) IN CAMPIONI BIOLOGICI UMANI E NELLA LINEA CELLULARE DI ADENOCARCINOMA DELLA PROSTATA LNCAP  
Dal 23-06-2009 al 26-06-2009
- **22.Roma - ABSTRACTS COMUNICATION OF THE 20st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) - Speaker: Matteo Ferro N°270, 271 , 273, 274 - dal 23-06-2010 al 25-06-2010**
- **23.Napoli -WorkShop XXI Congresso Nazionale SIUrO: [-2]proPSA e phi: novità in tema di diagnosi precoce del carcinoma prostatico - "Dati preliminari e sviluppi futuri" - 23-06-2011**
- **24.Napoli - ABSTRACTS COMUNICATION OF THE 21st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) - Speaker: Matteo Ferro N°48 , 198, 199,201, 202, 214 - dal 22-06-2011 al 24-06-2011**
- **25.Napoli - OPEN QUESTIONS IN PRACTICAL UROLOGY - "La diagnostica "di laboratorio: quale e quando" - dal 01-12-2011 al 02-12-2011**
- **26.Napoli - OPEN QUESTIONS IN PRACTICAL UROLOGY- "Lo screening: open questions" dal 01-12-2011 al 02-12-2011**
- **27.Napoli - OPEN QUESTIONS IN PRACTICAL UROLOGY - "IPB, prostatite e carcinoma prostatico: recenti implicazioni" - dal 01-12-2011 al 02-12-2011**
- **28.Bologna - XXII Congresso Nazionale Società Italiana di Urologia Oncologica (SIUrO) - Prof. Giuseppe Martorana - Presidente del Congresso - Il 2proPSA: un update - dal 13-06-2012 al 15-06-2012**
- **29.Bologna - ABSTRACTS COMUNICATION OF THE 22rd ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) - Speaker : Matteo Ferro N°105 ,110 ,153 160 - dal 13-06-2012 al 15-06-2012**
- **30.Napoli, Città della Scienza 2-5 luglio 2012 IV FORUM: Aggiornamento in tema di terapia delle malattie endocrine - Il ruolo delle gonadotropine e degli antiossidanti nell'approccio modern all'infertilità maschile: esperienze a confronto - dal 02-07-2012 al 05-07-2012**
- **31.Napoli,15 dicembre 2012- ACU (Associazione Campana Urologia) - Congresso Annuale - Ruolo del Laboratorio nella diagnosi del cancro della prostata - dal 15-12-2012 al 15-12-2012**
- **32."Attualità e prospettive in Urologia" - Napoli -Fitoterapici, infiammazione e ca prostatico- 07-06-2013**
- **33.Firenze - ABSTRACTS COMUNICATION OF THE 23rd ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) - Speaker: Matteo Ferro N°31 ,43, 44, 46, 56, 60 - dal 09-06-2013 al 11-06-2013**
- **34.Athens - Forum on Robotic Surgery in Urology - Obesity and Prostate cancer - dal 14-02-2014 al 15-02-2014**
- **35.Verona - I°Young Specialist - Renal Care - Tavola Rotonda: Applicazione delle linee guida terapeutiche nella pratica clinica - Nefrectomia: Quando, come e perché? - "Indicazioni" - dal 07-03-2014 al 08-03-2014**
- **36.Bologna - ABSTRACTS COMUNICATION OF THE 24th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) - Speaker: Matteo Ferro N°15, 19, 27, 28 - dal 22-06-2014 al 24-06-2014**
- **37.Madrid -1st Madrid Men's Health Meeting - Live Surgery Impianto Sling Virtue - 20-03-2015**
- **38.XXV CONGRESSO SIURO ROMA CORSO ECM 1: Il carcinoma prostatico oggi: dal sospetto alla diagnosi - "Le ricadute pratiche nell'attività clinica quotidiana" - dal 21-06-2015 al 23-06-2015**
- **39.Novità in tema di carcinoma della prostata e del rene- Caserta- Discussione Multidisciplinare - 20-10-2015**

- 40.**Roma 15° Congresso nazionale IEA - Live Surgery: Robotic assisted extended pelvic lymph node dissection (LND) - for prostatic cancer- Provoker - dal 25-02-2016 al 27-02-2016
- 41.**Roma 15° Congresso nazionale IEA - Live Surgery: Male sling procedure -Chirurgia in diretta - 27-02-2016
- 42.**FIMMG - NAPOLI - Progressi nell'ambito della diagnosi e cura del tumore prostatico: Focus sul trattamento - 18-06-2016
- 43.**SIRM (Congresso Nazionale della Società Italiana di Radiologia Medica e Interventistica SIRM) - Napoli - Neoplasie testicolari: inquadramento clinico - dal 15-09-2016 al 18-09-2016
- 44.**Il meeting SIUT regionale EMILIA-ROMAGNA - Quando il PSA non basta più: rapporto costo/beneficio nella pratica clinica dei marcatori urinari ed ematici di nuova generazione - 30-09-2016
- 45.**Convegno Associazione Campana di Urologia - Napoli- "Ca renale - protocolli di terapia neo-adiuvante" - 17-12-2016
- 46.**Napoli - INT :1st meeting uro news Nuove strategie diagnostiche e terapeutiche in uro oncologia- 4Kscore e rebiopsie: algoritmi matematici od uronews - dal 20-06-2017 al 21-06-2017
- 47.**Roma "Tor Vergata": PIU': il progetto integrato in urologia- Focus & Training - FOCUS SUL TUMORE DELLA PROSTATA: La basi biologiche della malattia - dal 21-06-2017 al 22-06-2017
- 48.**VII CONGRESSO NAZIONALE SIU - Venezia - Il ruolo dei marcatori ematici: cosa c'è di nuovo - dal 16-11-2017 al 18-11-2017
- 49.**XIX Congresso Nazionale SUN (Società Nuova Urologia) 2017- Palermo - Processi infiammatori prostatici ed il PSA nel trattamento dell'IPB -dal 30-11-2017 al 01-12-2017
- 50.**Convegno Annuale Associazione Campana di Urologia - Napoli- iXip e screening del tumore prostatico - 02-12-2017
- 51.**13° Congresso Nazionale Urop: Marcatori sierici, biopsia liquida e markers tissutali markers tissutali nell'era della Precision Medicine - dal 24-05-2018 al 26-05-2018
- 52.**RICCIONE 91° congresso nazionale - Società Italiana di Urologia -Live Surgery-Incontinenza urinaria maschile con sling suburetrale - dal 13-10-2018 al 16-10-2018
- 53.**VIII CONGRESSO NAZIONALE SIUT, FIRENZE-15 - 16 - 17 NOVEMBRE 2018 -TAVOLA ROTONDA: La gestione del k prostatico negli ambulatori urologici territoriali - Provokers - dal 15-11-2018 al 17-11-2018
- 54.**Bergamo-CONGRESSO SIURO LOMBARDIA E VENETO: DALLA SORVEGLIANZA - ALLA TERAPIA -AL FOLLOW-UP DEI TUMORI UROLOGICI - Il chirurgo: selezione dei pazienti per la sorveglianza attiva nella malattia MIBC: valutazione della risposta dopo trattamento neoadiuvante - cistoscopia con mapping o TURBT? -24-01-2019
- 55.**Bologna XXIX CONGRESSO NAZIONALE SIURo - DIBATTITO STRUTTURATO. TRATTAMENTO DEI PAZIENTI "UNRESPONSIVE" AL BCG - dal 11-04-2019 al 13-04-2019
- 56.**Milano: Advanced Course on robot-assisted radical prostatectomy", Processi infiammatori prostatici e PSA\* nel trattamento dell'IPB \* e PCa\* -Relatore e Faculty - dal 09-05-2019 al 10-05-2019
- 57.**Bologna: Congresso Nazionale Auro - Work-up dei pazienti con CTM e/o FISH test positive - Relatore e Faculty - dal 16-05-2019 al 18-05-2019
- 58.**14° Congresso Nazionale UrOP - Alberobello - BA Ospedale F. Miulli di Acquaviva delle - Fonti, all'interno della sessione di Live Surgery "Incontinenza urinaria maschile. Impianto Virtue". - dal 06-06-2019 al 08-06-2019
- 59.**Milano ISTITUTO EUROPEO DI ONCOLOGIA (IEO)-Laser Training Days -LECTURE: TEAM MULTIDISCIPLINARE INTRODUCTION - dal 19-06-2019 al 20-06-2019
- 60.**Milano ROBOT ASSISTED SURGERY TRAINING (IPSEN)- Lettura: Renal biopsy IEO experience: practical advice F.A. Mistretta 3 D Reconstruction supportive tools to improve oncological outcomes and to reduce ischemia time - dal 05-12-2019 al 06-12-2019
- 61.**Bergamo-CONGRESSO SIURO LOMBARDIA E VENETO: DALLA SORVEGLIANZA - ALLA TERAPIA - AL FOLLOW-UP DEI TUMORI UROLOGICI - Selezione dei pazienti per la sorveglianza attiva nella malattia MIBC: valutazione della risposta dopo trattamento neoadiuvante - cistoscopia con mapping o TURBT? - 24-01-2020
- 62.**Milano-Istituto Europeo di Oncologia: PROSTATE CANCER DIAGNOSIS: A NEW ERA From clinical nomograms to MRI-targeted biopsies -Nuovi markers urinari/plasmatici/genomici e biopsia liquida - 05-06-2020
- 63.**Il trattamento endoscopico delle neoplasie vescicali: tips and tricks -FAD Auro: Complete TUR in MIBC bladder sparing treatment - 26-10-2020
- 64.**RICERCA CLINICA E PATIENT ENGAGEMENT - dalla teoria alla pratica in URO-ONCOLOGIA 2020 Malattia refrattaria a BCG: quali alternative oggi per il paziente? - 14-11-2020
- 65.**XXVIII Congresso Nazionale Auro.it-Edizione Virtuale - UPDATE Profilassi delle recidive nel carcinoma vescicale non muscolo invasivo - Chemotherapy vs. Immunotherapy Choice and use - dal 20-05-2021 al 22-05-2021
- 66.**Riccione- 94° CONGRESSO NAZIONALE SIU (Società Italiana Di Urologia) -Tavola Rotonda Le Pubblicazioni Che Più Hanno Influenzato La Mia Pratica Clinica - dal 16-10-2021 al 19-10-2021
- 67.**RICERCA CLINICA E PATIENT ENGAGEMENT: DALLA TEORIA ALLA PRATICA IN URO-ONCOLOGIA 2021 Congresso online Formazione a distanza sincrona -Cistoscopia e instillazioni vescicali: problematiche di

frequenza su malattie di lunga durata. Quali i possibili effetti collaterali sull'uretra e come ridurre il fastidio/dolore in certe tipologie di pazienti; quali schedule di BCG e monitoraggio - 20-11-2021

•**68.**Modena- FORUM GUIDO MONZANI - 15° Congresso nazionale UrOP -Novità nel percorso diagnostico pre e post biopsia del Tumore Prostatico - dal 11-11-2021 al 13-11-2021

•**69.**Napoli- "IL RISULTATO IN CHIRURGIA ONCOLOGICA. LA SYNERGYA DELLE INTELLIGENZE" -Nuove prospettive nella diagnosi del cancro della prostata - dal 10-12-2021 al 11-12-2021

•**70.**Napoli - III° UrOnews National Meeting Nuove strategie diagnostiche e terapeutiche in uro-oncologia - Nutraceutica e flogosi uroteliale - dal 12-04-2022 al 13-04-2022

•**71.**Lazise (VR) - 16° Congresso Nazionale Urop - Focus On: Test Genetici in Uroncologia - dal 26-05-2022 al 28-05-2022

•**72.**SIUrO: INCARICO FAD ECM SIURO CORSO 13:30-15:30 -"Bladder sparing treatment per NMIBC ad alto rischio" - 09-09-2022

•**73.**69° CONVEGNO SUNI - TRATTAMENTO DEI TUMORI VESCICALI NON INVASIVI -Strategie di trattamento nell'era di BCG shortage - dal 23-09-2022 al 24-09-2022

•**74.**Milano IEO: Robot Assisted radical al partial nephrectomy - Casi clinici: calcolo del Padua, renal - 06-10-2022

•**75.**FIRENZE- XXXII Congresso Nazionale SIUrO -Dibattito strutturato BCG refractory - definizioni, soluzioni attuali e future: Diagnosi e selezione dei pazienti - dal 06-10-2022 al 08-10-2022

•**76.**FIRENZE- XXXII Congresso Nazionale SIUrO - L'attuale stato dell'arte del profilo genetico dei biomarker molecolari nei NMIBC ad alto rischio e il panorama immunitario - dal 06-10-2022 al 08-10-2022

•**77.**Milano - IEO: TUMORE DELLA PROSTATA - Innovazioni Nella Diagnosi, Stadiazione E Trattamento - Nuovi Biomarkers e test molecolari per la diagnosi precoce e la stratificazione del rischio - 28-10-2022

•**78.**Webinar SIU (SOCIETÀ ITALIANA DI UROLOGIA): ABC Neoplasia vescicale - Qual è il corretto follow-up del paziente affetto da neoplasia vescicale non muscolo invasiva? - 12-04-2023

•**79.**Castelfranco Veneto - Advanced Uro-Oncology Days IOV - PRIMA SESSIONE: Localized prostate cancer - Active surveillance and indication to genetic tests - dal 20-04-2023 al 21-04-2023

•**80.**Milano - Istituto Europeo di Oncologia - ADVANCED COURSE IN ROBOTIC SURGERY -LIVE SURGERY Prostatectomia radicale robot-assistita con linfadenectomia pelvica - dal 15-06-2023 al 16-06-2023

•**81.**FAD ASINCRONA SIUrO - Neoplasia uroteliale dell'alta via escrettrice -Quale nefroureterectomia e con che step chirurgici? - 14-07-2023

## **ATTIVITÀ GESTIONALI, ORGANIZZATIVE E DI SERVIZIO**

INCARICHI DI GESTIONE E AD IMPEGNI ASSUNTI IN ORGANI COLLEGIALI E COMMISSIONI, PRESSO RILEVANTI ENTI PUBBLICI E PRIVATI E ORGANIZZAZIONI SCIENTIFICHE E CULTURALI, OVVERO PRESSO L'ATENEO O ALTRI ATENEI

•**1)** Referente scientifico uro-oncologico del Comitato Tecnico Scientifico Valutatore della "Fondazione Muto Onlus" dal 01-12-2015 al 05-01-2019

•**2)** Cultore della materia in Urologia, abilitato ed ufficialmente inserito in Commissione d'esame di Semeiotica e patologia degli apparati 1 Settore Didattico Ospedale San Paolo - Università degli studi di Milano CdL Medicina - Blocco C - 3° piano per l'a.a.20/21 delibera del 13.01.21

•**3)** Cultore della materia in Urologia, abilitato ed ufficialmente inserito in Commissione d'esame di Semeiotica e patologia degli apparati 1 Settore Didattico Ospedale San Paolo - Università degli studi di Milano CdL Medicina - Blocco C - 3° piano per l'A.A. 21/22 delibera 18.02.22

•**4)** Cultore della materia in Urologia, abilitato ed inserito in Commissione d'esame di Semeiotica e patologia degli apparati 1 SPA, Università degli studi di Milano CdL Medicina Vialba per l'a.a.22/23.

- 5) Revisore per progetti di ricerca internazionali ammessi a finanziamento per: The Prostate Cancer Research Centre (PCRC) 23-24 Great James Street, London, WC1N 3ES., incarico del 12-08-2020
- 6) Visiting Professor presso Department of Urology of Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania FACULTATEA DE MEDICINĂ AA 20/21
- 7) Partecipazione a Școala Doctorală de la Universitatea de Medicină, Farmacie, Științe și Tehnologie "George Emil Palade" from Targu Mures, 540142, Romania AA20/21 - No.2/278/26.10.2020
- 8) Socio fondatore, consulente scientifico e responsabile Sperimentazioni Cliniche Spin Off accademica specializzata nella Diagnostica oncologica di laboratorio "ElicaDea" Università degli Studi di Napoli Federico II - dal 23-07-2020
- 9) Revisore Abstract Siu (Società Italiana di Urologia) - Anno 2022 e 2023.

#### **ATTIVITÀ CLINICO ASSISTENZIALI**

**Abilitato all'esercizio della professione nella 1° sessione del 2005 e iscritto all'Albo Provinciale dei Medici Chirurghi di SALERNO (Ordine della Provincia di SALERNO) dal 28-07-2005 con matricola n. 9252.**

•Referente per la gestione e valutazione urodinamica nel bilancio pre e post Trapianto renale "Università degli Studi di Napoli Federico II"- Chirurgia Generale e Trapianto D'Organo dal 01-12-2009 al 01-12-2011 in qualità di medico in Formazione Specialistica e successivamente di Dottorando di ricerca dal 22-10-2010 al 14.02.2012

•Attività clinico assistenziali, operatorie e di ricerca in qualità di Dottorando di ricerca A.F. di Urologia Oncologica ed Endourologia, Università degli Studi di Napoli Federico II - Direttore V. Altieri dal 22-10-2010 al 14-02-2012

•Attività di ricerca ed assistenziale in qualità di Dottorando di ricerca presso Ambulatorio integrato per la Diagnostica molecolare avanzata del carcinoma prostatico - Università degli studi di Napoli Federico II (A.F. di Urologia Oncologica ed Endourologia ed A.F. di Diagnostica Oncologica di laboratorio) - Ruolo: gestione attività di ricerca - dal 20-12-2010 al 31-01-2012

•Progetto Prostata - Screening Territoriale: Patrocinio ASL Salerno - dal 01-02-2013 al 01-03-2013

•Attività clinico assistenziali ed operatoria e di ricerca presso l'Azienda Universitaria Ospedaliera "San Giovanni di Dio e Ruggi D'Aragona" - Università degli Sudi di Salerno - dal 15-02-2012 al 31-03-2013

•Dirigente Medico Urologico - IEO - Istituto Europeo di Oncologia -Division of Urologic Cancer Surgery -Dal 01-05-2013 ad oggi

•Proctor per l'impianto di protesi per l'incontinenza urinaria post Prostatectomia Radicale - dal 12-07-2019 a oggi

## RIEPILOGO PROCEDURE CHIRURGICHE ESEGUITE NEGLI UTIMI 10 ANNI

- 1° OPERATORE: 1201

- 2° OPERATORE: 1110

Curriculum chirurgico nel settore Uro-Oncologico periodo 2013-2023, In qualità di 1° Operatore presso IEO - Istituto Europeo di Oncologia, suddiviso per tipologia di procedura:

- Cistectomia radicale con neovescica ileale ortotopica od ureteroileocutaneostomia od ureterocutaneostomia per neoplasia vescicale: N. 47
- Prostatectomie radicali robotiche con o senza Linfadenectomia pelvica: N. 324
- Chirurgia mininvasiva di correzione dell'incontinenza urinaria con impianto di sling e chirurgia uretrale per patologia oncologica (uretrectomia). N. 32
- Orchifuniculectomie con eventuale posizionamento di protesi per neoplasie testicolari: N. 52
- Nefrectomie radicali o parziali o nefroureterectomie con o senza piattello vescicale robotiche: N. 58
- Amputazione parziale pene ed amputazione totale pene con uretrostomia perineale per K pene. Trattamenti conservativi con glandulectomie parziali con uretroplastica e trattamenti conservativi mediante dissezione con laser Thulio: N. 34
- Resezione endoscopica e cistomapping di tumori vescicali: N. 459
- Cistoscopia con pielografia ascendente e/o posizionamento/rimozione stent ureterale mono o bilaterale per neoplasie uroteliali o per procedure radiologiche termoablativie. Ureterorenoscopie diagnostiche/operative per patologie neoplastiche o sospette dall'alta via escretrice: N. 116
- Uretrotomia endoscopica e/o meatotomia uretrale o resezione endoscopica prostatica per patologia non oncologica: N. 22
- Linfadenectomie pelviche/lomboaortiche robotiche per patologie oncologiche peniene, testicolari o ginecologiche: N. 15
- Linfadenectomie inguinali open e asportazione di linfonodo sentinella per K pene: N. 16
- Miscellanea di chirurgia minore: N. 21
- Chirurgia robotica per patologia benigna: N. 5

Data

27/07/2023

Luogo

Milano